US20010049523A1 - PMR catheter - Google Patents
PMR catheter Download PDFInfo
- Publication number
- US20010049523A1 US20010049523A1 US09/814,314 US81431401A US2001049523A1 US 20010049523 A1 US20010049523 A1 US 20010049523A1 US 81431401 A US81431401 A US 81431401A US 2001049523 A1 US2001049523 A1 US 2001049523A1
- Authority
- US
- United States
- Prior art keywords
- conductor
- catheter
- catheter assembly
- distal end
- elongate shaft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00392—Transmyocardial revascularisation
Definitions
- the present invention relates generally to devices and methods for promoting blood circulation to the heart muscle. More particularly, the present invention relates to devices and methods for forming holes or channels in the walls of a heart chamber such as those created during a percutaneous myocardial revascularization (PMR) procedure.
- PMR percutaneous myocardial revascularization
- a stenosis may be formed by an atheroma which is typically a harder, calcified substance which forms on the walls of a blood vessel.
- stenotic lesions have been treated with a number of medical procedures including coronary bypass surgery, angioplasty, and atherectomy.
- Coronary bypass surgery typically involves utilizing vascular tissue from another part of the patient's body to construct a shunt around the obstructed vessel.
- Angioplasty techniques such as percutaneous transluminal angioplasty (PTA) and percutaneous transluminal coronary angioplasty (PTCA) are relatively non-invasive methods of treating a stenotic lesion. These angioplasty techniques typically involve the use of a guidewire and a balloon catheter. In these procedures, a balloon catheter is advanced over a guidewire such that the balloon is positioned proximate a restriction in a diseased vessel.
- a third technique which may be used to treat a stenotic lesion is atherectomy. During an atherectomy procedure, the stenotic lesion is mechanically cut or abraded away from the blood vessel wall.
- Coronary bypass, angioplasty, and atherectomy procedures have all been found effective in treating individual stenotic lesions in relatively large blood vessels.
- the heart muscle is perfused with blood through a network of small vessels and capillaries.
- a large number of stenotic lesions may occur in a large number of locations throughout this network of small blood vessels and capillaries.
- the torturous path and small diameter of these blood vessels limit access to the stenotic lesions.
- the sheer number and small size of these stenotic lesions make techniques such as cardiovascular bypass surgery, angioplasty, and atherectomy impractical.
- PMR percutaneous myocardial revascularization
- a PMR procedure generally involves the creation of holes, craters or channels directly into the myocardium of the heart.
- PMR was inspired in part by observations that reptilian heart muscles are supplied with oxygen primarily by blood perfusing directly from within heart chambers to the heart muscle. This contrasts with the human heart, which is supplied by coronary vessels receiving blood from the aorta. Positive clinical results have been demonstrated in human patients receiving PMR treatments. These results are believed to be caused in part by blood flowing within a heart chamber through channels in myocardial tissue formed by PMR.
- Increased blood flow to the myocardium is also believed to be caused in part by the healing response to wound formation. Specifically, the formation of new blood vessels is believed to occur in response to the newly created wound. This response is sometimes referred to as angiogenisis.
- PMR improves a patient's condition through denervation. Denervation is the elimination of nerves endings. Specifically, the creation of wounds during a PMR procedure results in the elimination of nerve endings which were previously sending pain signals to the brain as a result of hibernating tissue.
- the present invention pertains to devices and methods for performing percutaneous myocardial revascularization (PMR).
- a device in accordance with the present invention may be used to form wounds in the myocardium of a patient's heart.
- PMR percutaneous myocardial revascularization
- this device may be used to form a channel wound (e.g., a wound with a depth greater than its width).
- this device may be used to form a crater wound (e.g., a wound with a width greater than its depth).
- a catheter in accordance with the present invention includes an elongate shaft having a proximal end and a distal end.
- the elongate shaft defines a lumen which extends substantially through the elongate shaft.
- An insulator is fixably attached to the elongate shaft at its distal end.
- the insulator includes at least two holes.
- the catheter also includes a conductor having a bent portion, a first leg portion and a second leg portion. The first and second leg portions of the conductor pass through the holes of the insulator and are disposed in the lumen of the catheter.
- the bent portion of the conductor substantially forms an electrode protruding from the distal end of the catheter.
- the distance which the electrode protrudes from the insulator is carefully controlled during the manufacture of the catheter. This helps to control the depth of the wounds which will be created with the catheter during a PMR procedure.
- the electrode proceeds to penetrate the heart until the insulator contacts the heart tissue.
- the insulator includes two landing zones which extend away from the electrode.
- the width of the landing zones is generally larger than the width of the electrode. The relatively large area of the landing zones assures that the travel of the electrode into the heart will stop when the landing zones contact the heart tissue.
- the landing zones extend beyond the wound created in the heart tissue during a PMR procedure. This is because the wounded tissue is substantially softened, and it is possible for a PMR catheter to be pushed through soft, injured tissue.
- a therapeutically effective wound will, at a minimum, perforate through the endocardium and damage blood vessels and capillaries in the myocardium.
- the likelihood of unintentionally perforating through the myocardium to the epicardium is reduced when the depth of the wound created is only enough to penetrate the endocardium adjacent the myocardium.
- the conductor defines a conductor lumen and at least one hole in fluid communication with the conductor lumen.
- the conductor lumen may be used during a PMR procedure to deliver fluid to the distal end of the catheter.
- the fluid delivered during the PMR procedure may include contrast, saline, therapeutic agents, etc.
- the fluid may be used for a number of tasks, including mapping a heart, marking an injury site or promoting angiogenic effects.
- pressurized fluid may be delivered to the wound site during or after wound formation.
- the formation of the wound may be enhanced by collateral damage to the myocardium induced by directing this pressurized fluid into the wound site.
- the impact of pressurized fluid causes vessels, capillaries and sinuses to rupture.
- a second benefit of this collateral damage is that the depth of the wounds required to achieve a therapeutic effect may be reduced.
- the injection of contrast creates a fluoroscopic marker of the treatment location.
- FIG. 1 is a plan view of the distal end of a catheter in accordance with the present invention.
- FIG. 2 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter shown in partial cross section;
- FIG. 3 is a plan view of a distal portion 22 of a catheter 20 in accordance with a bi-polar embodiment of the present invention
- FIG. 4 is a plan view of a distal portion 22 of a catheter 20 in accordance with a further bi-polar embodiment of the present invention.
- FIG. 5 is a plan view of a distal portion 22 of a catheter 20 in accordance with an additional bi-polar embodiment of the present invention.
- FIG. 6 is a plan view of the distal end of a catheter in accordance with the present invention.
- FIG. 7 is a plan view of the distal end of a catheter in accordance with the present invention.
- FIG. 8 is a plan view of a distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 9 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 10 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter shown in partial cross section;
- FIG. 11 is a plan view of the distal end of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 12 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 13 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 14 is a plan view of the distal portion of a catheter in accordance with the present invention.
- FIG. 15 is a perspective view of the distal end of the catheter including an alternate electrode assembly
- FIG. 16 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly
- FIG. 17 is a perspective view of the distal end of a catheter including another embodiment of an electrode assembly
- FIG. 18 is a perspective view of the distal end of the catheter including a further alternate embodiment of an electrode assembly
- FIG. 19 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly
- FIG. 20 is a perspective view of a distal end of a catheter including an alternate embodiment of an electrode assembly
- FIG. 21 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly.
- FIG. 22 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly.
- FIGS. 1 and 2 are plan views of a catheter 20 in accordance with the present invention.
- FIG. 1 is a plan view of a distal end 18 of catheter 20 .
- Catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown) and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate distal end 18 of catheter 20 .
- Insulator 32 includes a plurality of insulator lumens 34 .
- FIG. 2 a distal portion of catheter 20 is shown in partial cross-section.
- elongate shaft 24 includes a shaft lumen 36 .
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are disposed in lumen 36 of elongate shaft 24 .
- electrode 30 of catheter 20 is generally formed from bent portion 42 of conductor 40 .
- insulator 32 defines two holes 48 which are adapted to allow legs 44 , 46 of conductor 40 to pass through insulator 32 .
- conductor 40 is adapted to be connected to a radio frequency generator.
- One or more retaining elements 50 are formed on conductor 40 proximate insulator 32 .
- retaining elements 50 have been created by forming two kinks in conductor 40 . It will be understood that other embodiments of retaining elements 50 are possible without deviating from the spirit or scope of the present invention. It will also be understood that although two retaining elements are shown in FIG. 2, additional embodiments have been envisioned which utilize a single retaining element 50 .
- electrode 30 protrudes beyond insulator 32 of catheter 20 .
- the distance which electrode 30 protrudes is determined in part by the shape of bent region 42 of conductor 40 .
- the distance which electrode 30 protrudes is carefully controlled during the manufacture of catheter 20 . This helps to control the depth of the wounds which are created by catheter 20 during a PMR procedure. During such a procedure electrode 30 will proceed to penetrate the heart until insulator 32 contacts the heart tissue.
- insulator 32 includes two landing zones 60 which extend away from electrode 30 . In the embodiment of FIG. 1, the width of landing zones 60 is substantially greater than the width of electrode 30 .
- landing zones 60 assures that the travel of electrode 30 into the heart will stop when landing zones 60 contact the heart tissue. It is a desirable feature of this invention that landing zones 60 extend beyond the wound created in the heart tissue during a PMR procedure. This is because the wounded tissue is substantially softened, and it is possible for a PMR catheter to be pushed through soft, injured tissue.
- a therapeutically effective wound generally must perforate the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating the myocardium is reduced when the depth of wound created is only enough to penetrate the endocardium.
- the distance electrode 30 protrudes from landing zones 60 is between about 0.005 and about 0.4 inches. In a presently most preferred embodiment the distance electrode 30 protrudes from landing zones 60 is between about 0.010 and about 0.035 inches.
- the diameter of conductor 40 in bent portion 42 is between 0.003 and about 0.030 inches. In a presently most preferred embodiment, in accordance with FIG. 2, the diameter of conductor 40 in bent portion 42 is between about 0.008 and about 0.012 inches. It should be understood that the diameter of conductor 40 may vary along its length, and conductor 40 may include one or more tapered sections to optimize shaft support and flexibility. In a presently preferred embodiment, conductor 40 is about 70 inches long having a distal portion with a diameter of about 0.010 inches and a proximal portion with a diameter of about 0.022 inches. In this presently preferred embodiment, conductor 40 includes a transition portion which is about 8 inches long and which tapers from the diameter of the proximal portion to the diameter of the distal portion.
- the bend radius of electrode 30 is between about 0.004 and about 0.1 inches. In the presently most preferred embodiment in accordance with FIG. 2, the bend radius of electrode 30 is between about 0.012 and about 0.023 inches.
- the width of landing zones 60 extending from two sides of electrode 30 is between about 0.007 and about 0.050 inches. In a presently most preferred embodiment the width of landing zones 60 extending from two sides of electrode 30 is between about 0.015 and about 0.030 inches. As described above, and shown in FIG. 1, there are two landing zones 60 extending away from electrode 30 in the embodiment of FIGS. 1 and 2.
- the physician may prefer to penetrate the myocardium with electrode 30 a certain distance.
- the depth which electrode 30 penetrates heart tissue may be controlled by the geometry of electrode 30 and landing zones 60 .
- the distance which electrode 30 protrudes from landing zones 60 is carefully controlled during the manufacture of catheter 20 .
- a number of models of catheter 20 may be supplied to a physician, each model being adapted to produce wounds of a specific depth.
- the depth of the wound created is influenced by the depth which the electrode penetrates the heart tissue. Other factors may influence the depth of wound created without deviating from the spirit or scope of the present invention.
- the depth of wound created may be effected by the magnitude and frequency of the radiofrequency energy applied to electrode 30 .
- the depth of wound produced may be effected by the length of time the electrode is energized.
- Conductor 40 and electrode portion 30 may be comprised of stainless steel, Nitinol, or a number of other materials which are conductive and biocompatable. In a presently preferred embodiment, conductor 40 and electrode portion 30 are comprised of Nitinol. Embodiments of electrode 30 have also been envisioned wherein electrode 30 includes a radiopaque material. Examples of radiopaque material which may be included in electrode 30 include: gold, platinum, silver, and tungsten.
- Insulator 32 may be formed from ceramic, glass, glass-ceramic, polytetrafluoroethylene (PTFE), polyimide, or a number of other materials which are non-conductive and biocompatible and/or thermally insulated and biocompatible.
- insulator 32 is formed from ceramic.
- Further embodiments of insulator 32 have been envisioned which include a radiopaque material.
- the radiopaque materials which may be suitable for inclusion in an insulator 32 in some embodiments, include: gold, platinum, silver, tungsten, barium sulfide and bismuth oxide.
- a radiopaque material is selectively applied to the outer diameter of insulator 32 .
- a presently preferred radiopaque material is a platinum/iridium blend.
- conductor 40 in the embodiment of FIGS. 1 and 2 is circular in cross section, it should be understood that other cross-sectional shapes are possible without deviating from the spirit or scope of the invention.
- the cross-sectional shape of conductor 40 could be rectangular, square, triangular, oval, etc.
- elongate shaft 24 is comprised of polyether block amide (PEBA).
- PEBA polyether block amide
- Polyether block amide is commercially available from Atomchel Polymers of Birsdsboro Pa. under the trade name PEBAX.
- Elongate shaft 24 may be comprised of other materials without departing from the spirit of scope of this invention. Examples of materials which may be suitable in some applications include: polyethylene (PE), polypropylene (PP), polyvinylchloride (PVC), polyurethane, polyimide, and polytetrafluoroethylene (PTFE).
- insulator 32 and elongate shaft 24 are separate elements comprised of ceramic and PEBA respectively. However, it should be understood that these two elements could be combined into one element formed of one material without deviating from the spirit or scope of the present invention.
- elongate shaft 24 has a single lumen 36 . It will be understood that embodiments of the present invention have been envisioned in which shaft 26 has multiple lumens 36 .
- catheter 20 is preferably advanced through the vasculature of a patient until distal end 18 is proximate the endocardium of a patient's heart.
- the route taken by catheter 20 will normally be by way of the femoral artery and the aorta to the left ventricle.
- catheter 20 may enter the right ventricle by way of the pulmonary vein or femoral vein.
- catheter 20 may enter the right ventricle from the left ventricle by passing through the septal wall.
- catheter 20 may enter the body at the carotid artery and reach the heart therethrough.
- catheter 20 may include a slippery material disposed on the outer surfaces of elongate shaft 24 .
- distal end 18 of catheter 20 is positioned proximate the endocardium, preferably, such that electrode portion 30 is in contact with the endocardium. Electrode portion 30 may then be energized to form a wound.
- an additional step in a method in accordance with the present invention is to identify areas of tissue within the patient's heart which are candidates for PMR.
- areas of tissue in the heart muscle may be generally classified healthy or hibernating. Healthy tissue is tissue which is well perfused with blood, and subsequently well supplied with oxygen.
- Hibernating tissue is tissue which is not currently contracting to assist in the pumping of blood. However, if hibernating tissue is adequately supplied with blood, it will once again begin contracting and contribute to the pumping of blood.
- a number of methods may be used to identify hibernating tissue.
- contrast media may be injected into the coronary vessels to identify regions of the heart into which the contrast medium does not flow due to obstruction of the vessels into which the media was injected.
- the hibernating region will be identified by the lack of flow or abnormally low flow distally of the obstruction in the coronary vessel or vessels.
- a second method which may be used to identify hibernating regions of the heart involves injecting contrast media directly into the heart chambers. Hibernating tissue may then be identified by locating areas of generally poor wall motion of the heart chambers. When this method is selected, the contrast media may be delivered to the heart chambers via catheter 20 .
- Shaft lumen 36 and insulator lumens 34 of catheter 20 provide a suitable channel for delivering contrast media from a location outside the patient's body to distal end 18 of catheter 20 .
- Electrode 30 will be positioned proximate the targeted heart tissue.
- a contact detecting means in conjunction with electrode 30 will be used to sense contact between electrode 30 and heart tissue. This method is further detailed in a co-pending U.S. patent application Ser. No. ______, filed by the same assignee on even date herewith and entitled “Device and Method for Percutaneous Myocardial Revascularization.”
- electrode 30 will proceed to penetrate the heart until landing zones 60 of insulator 32 contact the heart tissue.
- landing zones 60 have a relatively large surface area to assure that the depth of electrode penetration will be controlled.
- the depth of the wound is also influenced by the distance which electrode 30 protrudes from landing zones 60 . As described above, this distance is carefully controlled during the manufacture of catheter 20 .
- the distance which electrode 30 protrudes from landing zones 60 and the relative surface areas of these elements are carefully selected to create a therapeutically effective wound while reducing the likelihood of unintentionally perforating the myocardium.
- a therapeutically effective wound will perforate through the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating the myocardium to the epicardium is reduced when the depth of wound created is only enough to penetrate the endocardium.
- a physician may desire to penetrate the myocardium with electrode 30 a certain distance.
- the depth which electrode 30 penetrates the heart tissue may be controlled by the geometry of electrode 30 and landing zones 60 .
- a number of models of catheter 20 may be provided to a physician, each model being adapted to create wounds of a particular depth.
- the depth of wound created is influenced by the depth which electrode 30 penetrates heart tissue. Other factors may influence wound depth without deviating from the spirit and scope of the present invention.
- the magnitude and frequency of the radiofrequency energy applied to electrode 30 may effect the depth of wound created during a PMR procedure.
- the length of time electrode 30 is energized may effect the depth of wound created.
- a fluid under pressure is forced into the wound by way of shaft lumen 36 and insulator lumens 34 .
- This fluid may include saline, radiopaque contrast media, a therapeutic agent, a caustic agent, or any combination of these.
- the formation of the wound may be enhanced by collateral damage to the myocardium induced by directing this pressurized fluid into the wound site.
- the impact of the pressurized fluid causes vessels, capillaries, and sinuses to rupture.
- By creating this collateral damage the number of wounds which must be made during a PMR procedure can be substantially reduced.
- Injecting a fluid including a radiopaque contrast media into the wound serves to create a radiopaque marker of the treatment site.
- Injecting a fluid, including a therapeutic agent serves to promote angiogenisis.
- Forcing fluid under pressure into the wound may be used to create collateral damage. Collateral damage is created when vessels, capillaries, and sinuses within the myocardium are ruptured. Thus collateral damage will increase the healing response of the body.
- the fluid under pressure may be forced into the wound while electrode 30 is energized or during a time when electrode 30 is not energized. In either case, the distal end of catheter 20 is positioned proximate the wound. Because electrode 30 was used to create the wound, catheter 20 is in an ideal position to inject fluid into the wound. If a separate catheter was used to deliver fluid, the distal end of that catheter would need to be positioned over the wound.
- a PMR system for use with catheter 20 may include a means for controlling the flow of fluid through catheter 20 .
- the means for controlling would direct fluid to be injected into the wound immediately after each spark.
- a PMR system for use with catheter 20 would include a foot pedal capable of activating the means for controlling fluid flow, and the means for energizing electrode 30 .
- fluid would flow from the distal end of catheter 20 while electrode 30 was energized.
- fluid may be delivered a set time after energy is delivered.
- a second benefit of collateral damage is that it may reduce the wound depth needed to create clinically effective results.
- the depth of the wound may be limited so that the wound just passes through the endocardium. Once the endocardium is perforated, pressure from infused fluid may be used to rupture myocardial vessels, capillaries and sinuses without further ablation or removal of tissue. As discussed previously, limiting the depth of ablation reduces the likelihood of unintentional myocardial perforation.
- catheter 20 may also be used in procedures where collateral damage is deemed undesirable. Collateral damage may be avoided by not delivering fluid through catheter 20 , or by delivering fluid through catheter 20 at a relatively low pressure.
- PMR improves a patient's condition through denervation. Specifically, the PMR induced wounds result in elimination of nerve endings which were previously sending pain signals to the brain as a result of hibernating tissue.
- the PMR procedure includes the step of delivering a therapeutic agent to the wound site via catheter 20 .
- Shaft lumen 36 and insulator lumens 34 of catheter 20 provide a suitable channel for delivering a therapeutic agent to the wound site from a location outside the patient's body.
- Fluids delivered via catheter 20 during a PMR procedure may provide additional benefits.
- fluid delivered via catheter 20 may serve to cool electrode 30 during a PMR procedure.
- fluid delivered via catheter 20 may serve to remove debris from the wound. It should be understood that steps may be omitted from the method described above, or the order of the steps may be changed without deviating from the spirit or scope of the present invention.
- catheter 20 may be used with bipolar or mono-polar PMR techniques.
- a return or neutral electrode is generally attached to the exterior of the patient.
- a return or neutral electrode is positioned in close proximity to distal end 18 of catheter 20 .
- a tubular return electrode may be disposed on the outer surface of catheter 20 proximate its distal end 18 .
- FIG. 3 is a plan view of a distal portion 22 of a catheter 20 .
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and a return electrode 332 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes a lumen 36 .
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are disposed in lumen 36 .
- Electrode 30 of catheter 20 is generally formed from bent portion 42 of conductor 40 .
- Return electrode 332 defines two holes 48 .
- Two sleeves 302 are disposed inside holes 48 .
- First leg 44 and second leg 46 pass through sleeves 302 .
- return electrode 332 is comprised of a conductive material allowing it to serve as a return electrode in a bi-polar PMR configuration.
- Sleeves 302 are comprised of a non-conductive material, and serve to insulate conductor 40 from return electrode 332 .
- a return conductor 304 is coupled to return electrode 332 .
- Return conductor 332 is suitably insulated so that it will not make electrical contact with conductor 40 .
- return conductor 332 is disposed in a separate lumen of elongate shaft 24 .
- FIG. 4 is a plan view of a distal portion 22 of a catheter 20 in accordance with a bi-polar embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes a lumen 36 .
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are disposed in lumen 36 .
- Electrode 30 of catheter 20 is generally formed from bent portion 42 of conductor 40 .
- Insulator 32 defines two holes 48 which are adapted to allow legs 44 , 46 of conductor 40 to pass through insulator 32 .
- a return electrode 332 is disposed about the outer surface of insulator 32 .
- Return electrode 332 is comprised of a conductive material allowing it to serve as a return electrode in a bi-polar PMR configuration.
- a return conductor 304 is coupled to return electrode 332 .
- Return conductor 332 is suitably insulated so that it will not make electrical contact with conductor 40 .
- return conductor 332 is disposed in a separate lumen of elongate shaft 24 . As shown in FIG. 4, return electrode 332 protrudes beyond the distal end of elongate shaft 24 .
- FIG. 5 is a plan view of a distal portion 22 of a catheter 20 in accordance with a bi-polar embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 is comprised of an outer tubular member 312 and an inner tubular member 310 having a lumen 36 .
- a conductive coating 314 is disposed on the outer diameter of inner tubular member 310 .
- Outer tubular member 312 is comprised of a non-conductive material and generally overlays conductive coating 314 .
- outer tubular member 312 is comprised of shrink tubing.
- outer tubular member 312 is comprised of a nonconductive coating.
- a portion of conductive coating 314 proximate distal end 18 is not covered by outer tubular member 312 .
- Embodiments of the present invention have been envisioned in which exposed portions of conductive coating 314 act as a return electrode.
- a return electrode 316 is disposed about and electrically coupled to conductive coating 314 .
- return electrode 316 is comprised of a material which is conductive and radiopaque. Examples of suitable materials include gold, platinum, silver, and tungsten.
- conductive coating 314 acts as an electrical conductor coupling return electrode 316 to the radio frequency generator used in a PMR procedure.
- Catheter 20 of FIG. 5 also includes an electrode 30 generally formed from bent portion 42 of conductor 40 .
- conductor 40 is electrically coupled to a radio frequency generator (not shown) by a cable (not shown). In a presently preferred embodiment, conductor 40 is directly attached to the cable.
- FIG. 6 is a plan view of a distal portion 22 of a catheter 20 in accordance with one embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and a insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes a lumen 36 .
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are disposed in lumen 36 .
- Electrode 30 of catheter 20 is generally formed from bent portion 42 of conductor 40 .
- Insulator 32 defines two holes 48 which are adapted to allow legs 44 , 46 of conductor 40 to pass through insulator 32 .
- a groove 340 is disposed on the outer diameter of insulator 32 .
- a band 342 is disposed in groove 340 .
- band 342 is comprised of a radiopaque material.
- band 342 aids the physician in locating distal end 18 of catheter 20 .
- Band 342 may be comprised of a number of radiopaque materials including gold, platinum, silver, tungsten, barium sulfate, and bismuth oxide.
- band 342 is a platinum/iridium blend.
- FIGS. 7 and 8 illustrate an additional embodiment of catheter 20 .
- FIG. 8 is a plan view of distal portion 22 of catheter 20 shown in partial cross section.
- FIG. 7 is a plan view of distal end 18 of the embodiment of catheter 20 shown in FIG. 8.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), a distal portion 22 , and a distal end 18 .
- An electrode portion 30 and an insulator 32 are disposed proximate distal end 18 of catheter 20 .
- insulator 32 includes two landing zones 60 which extend away from electrode 30 .
- elongate catheter 20 includes a conductor 140 having a bent portion 142 , a first leg 144 , and a second leg 146 .
- Conductor 140 also defines a lumen 200 and two holes 202 which are in fluid communication with lumen 200 . Holes 202 in conductor 40 are shown most clearly in FIG. 7.
- First leg 144 and second leg 146 are disposed in lumen 36 of elongate shaft 24 .
- Electrode 30 is generally formed from bent portion 142 of conductor 140 .
- insulator 32 defines two holes 48 which are adapted to allow legs 144 , 146 of conductor 140 to pass through insulator 32 .
- a retaining element 150 is formed on conductor 140 proximate insulator 32 .
- retaining element 150 has been created by forming a weld bead 204 on conductor 140 .
- Weld bead 204 may be formed using a number of manufacturing processes. For example, welding, solder, and brazing are all suitable processes of creating weld bead 204 . It will be understood that other embodiments of retaining element 150 are possible without deviating from the spirit or scope of the present invention.
- weld bead 204 also serves the function of sealing the end of lumen 200 .
- electrode 30 protrudes beyond insulator 32 of catheter 20 .
- the distance which electrode 30 protrudes is determined in part by the shape of bent region 142 of conductor 140 .
- the distance which electrode 30 protrudes is carefully controlled during the manufacture of catheter 20 . This helps to control the depth of the wounds created by catheter 20 during a PMR procedure. During such a procedure electrode 30 will proceed to penetrate the heart until insulator 32 contacts the heart tissue.
- insulator 32 includes two landing zones 60 which extend away from electrode 30 .
- the width of landing zones 60 is substantially greater than the width of electrode 30 in FIG. 7.
- the relatively large area of landing zones 60 assure that the travel of electrode 30 into the heart tissue will stop when landing zones 60 contact the heart tissue. It is a desirable feature of this invention that landing zones 60 generally extend beyond the wound created in the heart tissue created during a PMR procedure. This is because the wounded tissue is substantially softened, and it is possible for a PMR catheter to be pushed through soft, injured tissue.
- the distance which electrode 30 protrudes from landing zones 60 and the relative surface areas of these elements are carefully selected to create a therapeutically effective wound while reducing the likelihood of unintentionally perforating the myocardium.
- a therapeutically effective wound will at a minimum perforate through the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating through the myocardium to the epicardium is reduced when the depth of wound created is only enough to penetrate the endocardium.
- catheter 20 is preferably advanced through the vasculature of a patient until distal end 18 is proximate the endocardium of the patient's heart.
- the route taken by catheter 20 will normally be by way of the femoral artery and the aorta to the left ventricle.
- the right ventricle may be accessed via the pulmonary vein or the femoral vein.
- the septal approach may be used. In a septal approach, the distal end of catheter 20 first enters one ventricle (the left or the right). A PMR procedure may be performed in that ventricle. The distal end of catheter 20 may then enter the other ventricle by passing through the septal wall.
- a third example of a route which may be taken by catheter 20 is a route via the carotid artery.
- catheter 20 may include a slippery material disposed on the outer surfaces of elongate shaft 24 .
- distal end 18 of catheter 20 is positioned proximate the endocardium, preferably, such that electrode portion 30 is in contact with the endocardium. Contact between the endocardium and electrode 30 may be detected electronically.
- a method is further detailed in co-pending U.S. patent application Ser. No. ______, filed by the same assignee on even date herewith and entitled “Device and Method for Percutaneous Myocardial Revascularization.”. The disclosure of this co-pending application is hereby incorporated by reference into the present application.
- An additional method which may be used to determine the location of electrode 30 is through radiographic techniques.
- the use of radiographic techniques may be enhanced by selectively incorporating radiopaque material into catheter 20 .
- a radiopaque material is disposed about the outer diameter of insulator 32 .
- the radiopaque material may be comprised of a band of metal. Materials which may be suitable for this marker band include: gold, platinum, silver, and tungsten.
- a radiopaque material may also be included in electrode 30 and/or insulator 32 .
- an additional step in a method in accordance with the present invention is to identify areas of tissue within the patient's heart which are candidates for PMR.
- areas of tissue in the heart muscle may be generally classified healthy or hibernating. Healthy tissue is tissue which is well perfused with blood, and subsequently well supplied with oxygen.
- Hibernating tissue is tissue which is not currently contracting to assist in the pumping of blood. However, if hibernating tissue is adequately supplied with blood, it will once again begin contracting and contribute to the pumping of blood.
- a number of methods may be used to identify hibernating tissue.
- contrast media may be injected into the coronary vessels to identify regions of the heart into which the contrast medium does not flow due to obstruction of the vessels into which the media was injected.
- the hibernating region will be identified by the lack of flow or abnormally low flow distally of the obstruction in the coronary vessel or vessels.
- a second method which may be used to identify hibernating regions of the heart involves injecting contrast media directly into the heart chambers. Hibernating tissue may then be identified by locating areas of generally poor wall motion of the heart chambers. When this method is selected, the contrast media may be delivered to the heart chambers via catheter 20 . Lumen 200 and holes 202 of conductor 140 provide a channel for delivering contrast media from a location outside the patients body to distal end 18 of catheter 20 .
- these regions are candidates for PMR.
- electrode 30 will proceed to penetrate the heart until landing zones 60 of insulator 32 contact the heart tissue.
- landing zones 60 have a relatively large surface area to assure that the depth of the wound will be controlled.
- the depth of the wound is also controlled by the distance which electrode 30 protrudes from landing zones 60 . As described above, this distance is carefully controlled during the manufacture of catheter 20 .
- a therapeutically effective wound generally will, at a minimum, perforate through the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating through the myocardium to the epicardium is reduced when the depth of wound created is only enough to penetrate the endocardium.
- a fluid under pressure is forced into the wound through lumen 200 and holes 202 of conductor 140 .
- This fluid may include saline, contrast media, a therapeutic agent, a caustic agent, or any combination of these.
- the formation of the wound may be enhanced by collateral damage to the myocardium induced by directing this pressurized fluid into the wound site.
- the impact of the pressurized fluid causes vessels, capillaries, and sinuses to rupture.
- the number of wounds which need to be made during a PMR procedure may be substantially reduced.
- a second benefit of collateral damage is that it may reduce the wound depth needed to create clinically effective results.
- the depth of the wound may be limited so that the wound just passes through the endocardium.
- pressure from infused fluid may be used to rupture the myocardial vessels, capillaries and sinuses without further ablation or removal of tissue. Limiting the depth of ablation reduces the likelihood of unintentional myocardial perforation.
- the injection of a fluid containing a radiopaque contrast solution creates a fluoroscopic marker of the treatment location.
- holes 202 disposed at the distal end of catheter 20 are that they permit the fluid to be injected into the wound immediately after it is created.
- the PMR procedure includes the step of delivering a therapeutic agent though lumen 200 and holes 202 of conductor 140 .
- a fluid is delivered via catheter 20 to the patient proximate the wound.
- This fluid may include saline, radiopaque contrast media, a therapeutic agent, a caustic agent, or any combination of these.
- Injecting a fluid including a radiopaque contrast media acts to create a radiopaque marker of the treatment site.
- Injecting a fluid into a wound which includes a therapeutic agent acts to enhance the angiogenisis response of the body.
- An embodiment of the present invention has been envisioned where the same control means which enables radiofrequency energy to energize electrode 30 may be used to enable fluid to be injected into the wound from the distal end of catheter 20 .
- the control means of the PMR system directs fluid to be injected into the wound immediately after each spark.
- Fluids delivered via catheter 20 during a PMR procedure may provide additional benefits.
- fluid delivered via lumen 200 of conductor 140 may serve to cool electrode 30 during a PMR procedure.
- fluid delivered via catheter 20 may serve to remove debris from the wound. It should be understood that steps may be omitted from the method described above, or the order of the steps may be changed without deviating from the spirit or scope of the present invention.
- FIG. 9 is a plan view of a distal portion 22 of a catheter 20 in accordance with an alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes two lumens 36 A, 36 B.
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are disposed in lumens 36 A and 36 B respectively.
- Electrode 30 of catheter 20 is general formed from bent portion 42 of conductor 40 .
- Insulator 32 defines two holes 48 which are adapted to allow legs 44 , 46 of conductor 40 to pass through insulator 32 .
- Insulator 32 defines additional holes (not shown) which allow fluid to pass therethrough.
- each retaining element 50 is located on conductor 40 proximate insulator 32 .
- each retaining element 50 is a sleeve surrounding conductor 40 .
- Each retaining element 50 has been fixed to conductor 40 with a crimping process.
- Retaining elements 50 assist in maintaining the position of bent portion 42 ; preventing it from moving before, or during a PMR procedure.
- Insulator 32 acting in conjunction with retaining elements 50 , supports bent portion 42 of conductor 40 , preventing it from being deformed during a PMR procedure.
- FIG. 10 is a plan view of a distal portion 22 of a catheter 20 in accordance with an alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- Elongate shaft 24 includes two lumens 36 A, 36 B.
- Catheter 20 includes a conductor 640 having a bent portion 642 , a first portion 652 , and a second portion 654 . As shown in FIG. 10, the outer diameter of second portion 654 is smaller than the outer diameter of first portion 652 .
- Conductor 640 includes a step 650 proximate the intersection between first portion 652 and second portion 654 .
- First portion 652 of conductor 640 is substantially disposed in lumen 36 A of elongate shaft 24 .
- Second portion 654 of conductor 640 passes through insulator 32 via two holes 48 .
- the remaining portion of second portion 654 is disposed in lumen 36 B of elongate shaft 24 .
- a bent portion 642 of conductor 640 extends beyond insulator 32 ; an electrode 30 is general formed by bent portion 642 .
- a retaining element 50 is located on second portion 654 proximate insulator 32 .
- retaining element 50 is a sleeve surrounding conductor 640 .
- a number of processes may be used to fix retaining element 50 onto conductor 640 .
- Other examples of acceptable retention methods include soldering, brazing, welding, crimping, and adhering with an adhesive.
- Retaining element 50 and step 650 assist in maintaining the position of bent portion 642 ; preventing it from moving before, or during a PMR procedure.
- Insulator 32 acting in conjunction with retaining element 50 , supports bent portion 642 of conductor 640 , preventing it from being deformed during a PMR procedure.
- FIG. 11 is a plan view of a distal portion 22 of a catheter 20 in accordance with an alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes a lumen 36 .
- Catheter 20 includes a conductor 740 having a bent portion 742 , a first leg 744 , and a second leg 746 .
- First leg 744 and second leg 746 are substantially disposed in lumen 36 .
- Electrode 30 of catheter 20 is general formed by bent portion 742 of conductor 740 .
- Insulator 32 defines two holes 48 which are adapted to allow legs 744 , 746 of conductor 740 to pass through insulator 32 .
- a bond 750 is formed between first leg 744 and second leg 746 of conductor 740 .
- a number of process may be used to create bond 750 .
- bond 750 may be created by applying an adhesive between first leg 744 and second leg 746 .
- Other techniques which may be used to fabricate bond 750 include welding, brazing, and soldering.
- FIG. 12 is a plan view of a distal portion 22 of a catheter 20 in accordance with an alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes two lumens 36 A, 36 B.
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are substantially disposed in lumens 36 A and 36 B respectively.
- Electrode 30 of catheter 20 is general formed from bent portion 42 of conductor 40 .
- Insulator 32 defines two holes 48 which are adapted to allow legs 44 , 46 of conductor 40 to pass through insulator 32 .
- each retaining element 50 is located on conductor 40 proximate insulator 32 .
- each retaining element 50 is formed from material of conductor 40 which has been displaced to create a localized area with a greater width. A crimping or staking process may be used to create deformations of this type in conductor 40 .
- Retaining elements 50 assist in maintaining the position of bent portion 42 ; preventing it from moving before, or during a PMR procedure.
- Insulator 32 acting in conjunction with retaining elements 50 supports bent portion 42 of conductor 40 , preventing it from being deformed during a PMR procedure.
- FIG. 13 is a plan view of a distal portion 22 of a catheter 20 in accordance with an alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes two lumens 36 A, 36 B.
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are substantially disposed in lumens 36 A and 36 B respectively.
- Electrode 30 of catheter 20 is general formed from bent portion 42 of conductor 40 .
- Insulator 32 defines two holes 48 which are adapted to allow legs 44 , 46 of conductor 40 to pass through insulator 32 .
- Conductor 40 is fixed to insulator 32 by two adhesive bonds 902 A, 902 B which prevent bent portion 42 from moving before, or during a PMR procedure.
- Insulator 32 acting in conjunction with adhesive bonds 902 A, 902 B supports bent portion 42 of conductor 40 , preventing it from being deformed during a PMR procedure.
- FIG. 14 is a plan view of a distal portion 22 of a catheter 20 in accordance with an alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- An electrode portion 30 and an insulator 32 are disposed proximate a distal end 18 of catheter 20 .
- elongate shaft 24 includes two lumens 36 A, 36 B.
- Catheter 20 includes a conductor 40 having a bent portion 42 , a first leg 44 , and a second leg 46 .
- First leg 44 and second leg 46 are substantially disposed in lumens 36 A and 36 B respectively.
- Electrode 30 of catheter 20 is general formed from bent portion 42 of conductor 40 .
- Insulator 32 defines two holes 48 which are adapted to allow legs 44 , 46 of conductor 40 to pass through insulator 32 .
- lumens 36 A, 36 B of elongate shaft 24 are substantially filled with potting material 950 .
- Potting material 950 serves to fix the location of conductor 30 relative to insulator 32 and elongate shaft 24 .
- Potting material 950 may be comprised of a number of materials. Examples of suitable materials include silicone rubber and urethane.
- Catheter 20 and insulator 32 may include additional lumens (not shown in FIG. 14) which allow a fluid to be conducted from proximal end 26 of catheter 20 to distal end 18 of catheter 20 .
- FIG. 15 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 is comprised of a conductor 932 which is generally cylindrical in shape.
- electrode 930 is energized with radio frequency energy causing it to create a wound.
- electrode 930 penetrates the tissue of the heart. Electrode 930 continues penetrating heart tissue until distal end 910 of elongate shaft 24 contacts the surface of the heart tissue.
- FIG. 16 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an additional alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 is comprised of two conductors 934 and 936 . Conductors 934 and 936 are both generally cylindrical in shape.
- electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation, electrode 930 penetrates the tissue of the heart. Electrode 930 continues penetrating heart tissue until distal end 910 of elongate shaft 24 contacts the surface of the heart tissue.
- FIG. 17 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an additional alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 is comprised of two conductors 938 and 940 . Conductors 938 and 940 are both generally arch shaped.
- electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation, electrode 930 penetrates the tissue of the heart. Electrode 930 continues penetrating heart tissue until distal end 910 of elongate shaft 24 contacts the surface of the heart tissue.
- FIG. 18 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an additional alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 is comprised of a straight portion 942 and a curved portion 944 .
- electrode 930 is energized with radio frequency energy causing it to create a wound.
- electrode 930 penetrates the tissue of the heart. Electrode 930 continues penetrating heart tissue until distal end 910 of elongate shaft 24 contacts the surface of the heart tissue.
- FIG. 19 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an additional alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 is comprised of a straight portion 946 and a ring portion 948 .
- electrode 930 is energized with radio frequency energy causing it to create a wound.
- electrode 930 penetrates the tissue of the heart. Electrode 930 continues penetrating heart tissue until distal end 910 of elongate shaft 24 contacts the surface of the heart tissue.
- FIG. 20 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an additional alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 includes two straight portions 952 and 954 projecting from distal end 910 of elongate shaft 24 .
- Electrode 930 also includes a hoop portion 956 having two ends 958 .
- Electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation, electrode 930 penetrates the tissue of the heart. Electrode 930 continues penetrating heart tissue until distal end 910 of elongate shaft 24 contacts the surface of the heart tissue.
- FIG. 21 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an additional alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 includes two straight portions 962 and 964 projecting from distal end 910 of elongate shaft 24 .
- Electrode 930 also includes an interconnecting portion 966 having two ends 968 .
- interconnecting portion 966 is joined to the distal end of straight portion 962 .
- the other end 968 of interconnecting portion 966 is joined to the distal end of straight portion 964 .
- interconnecting portion 966 is generally “U” shaped.
- FIG. 22 is a perspective view of a distal portion 22 of a catheter 20 in accordance with an additional alternate embodiment of the present invention.
- catheter 20 includes an elongate shaft 24 , a proximal end 26 (not shown), and a distal portion 22 .
- Elongate shaft 24 includes a distal end 910 .
- An electrode 930 projects from distal end 910 of elongate shaft 24 .
- electrode 930 includes two straight portions 972 and 974 projecting from distal end 910 of elongate shaft 24 .
- Electrode 930 also includes an interconnecting portion 976 having two ends 978 .
- interconnecting portion 976 is joined to the distal end of straight portion 972 .
- the other end 978 of interconnecting portion 976 is joined to the distal end of straight portion 974 .
- interconnecting portion 976 is generally “S” shaped.
- a PMR method in accordance with the present invention may include the step of delivering a fluid to the wound site via catheter 102 .
- Contact detecting means 706 may be used to verify that distal end 18 is proximate myocardial tissue before delivering the fluid.
- This fluid may include saline, radiopaque contrast media, a therapeutic agent, a caustic agent, or any combination of these.
- Injecting a fluid including a radiopaque contrast media into the wound serves to create a radiopaque marker of a treatment site.
- Injecting a fluid, including a therapeutic agent serves to promote angiogenisis.
- the formation of the wound may also be enhanced by collateral damage to the myocardium induced by directing pressurized fluid into the wound site. The impact of the pressurized fluid causes vessels, capillaries, and sinuses to rupture.
Abstract
Devices and methods for performing percutaneous myocardial revascularization (PMR). A catheter in accordance with the invention includes an elongate shaft having a proximal end and a distal end. The elongate shaft defines a lumen, and a conductor is disposed inside the lumen. An electrode portion is formed by the bent portion of the conductor which extends from the distal end of the elongate shaft. A method in accordance with the present invention may be used to form a wound through the endocardium and into the myocardium of a patient's heart. Collateral damage to the myocardium may be created by infusing pressurized fluid into the wound. A number of fluids may be delivered to a location proximate the wound via the catheter.
Description
- The present application is related to U.S. patent application Ser. No. ______, filed by the same assignee on even date herewith and entitled “Device and Method for Percutaneous Myocardial Revascularization.”
- The present invention relates generally to devices and methods for promoting blood circulation to the heart muscle. More particularly, the present invention relates to devices and methods for forming holes or channels in the walls of a heart chamber such as those created during a percutaneous myocardial revascularization (PMR) procedure.
- Assuring that the heart muscle is adequately supplied with oxygen is critical to sustaining the life of a patient. To receive an adequate supply of oxygen, the heart muscle must be well perfused with blood. In a healthy heart, blood perfusion is accomplished with a system of blood vessels and capillaries. However, it is common for the blood vessels to become occluded (blocked) or stenotic (narrowed). A stenosis may be formed by an atheroma which is typically a harder, calcified substance which forms on the walls of a blood vessel.
- Historically, individual stenotic lesions have been treated with a number of medical procedures including coronary bypass surgery, angioplasty, and atherectomy. Coronary bypass surgery typically involves utilizing vascular tissue from another part of the patient's body to construct a shunt around the obstructed vessel. Angioplasty techniques such as percutaneous transluminal angioplasty (PTA) and percutaneous transluminal coronary angioplasty (PTCA) are relatively non-invasive methods of treating a stenotic lesion. These angioplasty techniques typically involve the use of a guidewire and a balloon catheter. In these procedures, a balloon catheter is advanced over a guidewire such that the balloon is positioned proximate a restriction in a diseased vessel. The balloon is then inflated and the restriction in the vessel is opened. A third technique which may be used to treat a stenotic lesion is atherectomy. During an atherectomy procedure, the stenotic lesion is mechanically cut or abraded away from the blood vessel wall.
- Coronary bypass, angioplasty, and atherectomy procedures have all been found effective in treating individual stenotic lesions in relatively large blood vessels. However, the heart muscle is perfused with blood through a network of small vessels and capillaries. In some cases, a large number of stenotic lesions may occur in a large number of locations throughout this network of small blood vessels and capillaries. The torturous path and small diameter of these blood vessels limit access to the stenotic lesions. The sheer number and small size of these stenotic lesions make techniques such as cardiovascular bypass surgery, angioplasty, and atherectomy impractical.
- When techniques which treat individual lesions are not practical a technique know as percutaneous myocardial revascularization (PMR) may be used to improve the oxygenation of the myocardial tissue. A PMR procedure generally involves the creation of holes, craters or channels directly into the myocardium of the heart. PMR was inspired in part by observations that reptilian heart muscles are supplied with oxygen primarily by blood perfusing directly from within heart chambers to the heart muscle. This contrasts with the human heart, which is supplied by coronary vessels receiving blood from the aorta. Positive clinical results have been demonstrated in human patients receiving PMR treatments. These results are believed to be caused in part by blood flowing within a heart chamber through channels in myocardial tissue formed by PMR. Increased blood flow to the myocardium is also believed to be caused in part by the healing response to wound formation. Specifically, the formation of new blood vessels is believed to occur in response to the newly created wound. This response is sometimes referred to as angiogenisis. In addition to promoting increased blood flow, it is also believed that PMR improves a patient's condition through denervation. Denervation is the elimination of nerves endings. Specifically, the creation of wounds during a PMR procedure results in the elimination of nerve endings which were previously sending pain signals to the brain as a result of hibernating tissue.
- The present invention pertains to devices and methods for performing percutaneous myocardial revascularization (PMR). A device in accordance with the present invention may be used to form wounds in the myocardium of a patient's heart. Several general types of wounds may be created with this device. For example, this device may be used to form a channel wound (e.g., a wound with a depth greater than its width). By way of a second example, this device may be used to form a crater wound (e.g., a wound with a width greater than its depth).
- In a preferred embodiment, a catheter in accordance with the present invention includes an elongate shaft having a proximal end and a distal end. The elongate shaft defines a lumen which extends substantially through the elongate shaft. An insulator is fixably attached to the elongate shaft at its distal end. The insulator includes at least two holes. The catheter also includes a conductor having a bent portion, a first leg portion and a second leg portion. The first and second leg portions of the conductor pass through the holes of the insulator and are disposed in the lumen of the catheter. The bent portion of the conductor substantially forms an electrode protruding from the distal end of the catheter.
- The distance which the electrode protrudes from the insulator is carefully controlled during the manufacture of the catheter. This helps to control the depth of the wounds which will be created with the catheter during a PMR procedure. In a presently preferred embodiment of the present invention, the electrode proceeds to penetrate the heart until the insulator contacts the heart tissue.
- The insulator includes two landing zones which extend away from the electrode. The width of the landing zones is generally larger than the width of the electrode. The relatively large area of the landing zones assures that the travel of the electrode into the heart will stop when the landing zones contact the heart tissue.
- It is a desirable feature of this invention that the landing zones extend beyond the wound created in the heart tissue during a PMR procedure. This is because the wounded tissue is substantially softened, and it is possible for a PMR catheter to be pushed through soft, injured tissue.
- The distance which the electrode protrudes from the landing zone and the relative surface areas of these elements are carefully selected to create a therapeutically effective wound while reducing the likelihood of unintentionally perforating the myocardium. Preferably, a therapeutically effective wound will, at a minimum, perforate through the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating through the myocardium to the epicardium is reduced when the depth of the wound created is only enough to penetrate the endocardium adjacent the myocardium.
- In one embodiment of a device in accordance with the present invention, the conductor defines a conductor lumen and at least one hole in fluid communication with the conductor lumen. The conductor lumen may be used during a PMR procedure to deliver fluid to the distal end of the catheter. The fluid delivered during the PMR procedure may include contrast, saline, therapeutic agents, etc. The fluid may be used for a number of tasks, including mapping a heart, marking an injury site or promoting angiogenic effects.
- In a presently preferred method in accordance with the present invention, pressurized fluid may be delivered to the wound site during or after wound formation. The formation of the wound may be enhanced by collateral damage to the myocardium induced by directing this pressurized fluid into the wound site. The impact of pressurized fluid causes vessels, capillaries and sinuses to rupture. By creating this collateral damage, the number of wounds which need be made during a PMR procedure may be substantially reduced. A second benefit of this collateral damage is that the depth of the wounds required to achieve a therapeutic effect may be reduced. In addition, the injection of contrast creates a fluoroscopic marker of the treatment location.
- FIG. 1 is a plan view of the distal end of a catheter in accordance with the present invention;
- FIG. 2 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter shown in partial cross section;
- FIG. 3 is a plan view of a
distal portion 22 of acatheter 20 in accordance with a bi-polar embodiment of the present invention; - FIG. 4 is a plan view of a
distal portion 22 of acatheter 20 in accordance with a further bi-polar embodiment of the present invention; - FIG. 5 is a plan view of a
distal portion 22 of acatheter 20 in accordance with an additional bi-polar embodiment of the present invention; - FIG. 6 is a plan view of the distal end of a catheter in accordance with the present invention;
- FIG. 7 is a plan view of the distal end of a catheter in accordance with the present invention;
- FIG. 8 is a plan view of a distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 9 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 10 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter shown in partial cross section;
- FIG. 11 is a plan view of the distal end of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 12 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 13 is a plan view of the distal portion of a catheter in accordance with the present invention with the catheter being shown in partial cross section;
- FIG. 14 is a plan view of the distal portion of a catheter in accordance with the present invention;
- FIG. 15 is a perspective view of the distal end of the catheter including an alternate electrode assembly;
- FIG. 16 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly;
- FIG. 17 is a perspective view of the distal end of a catheter including another embodiment of an electrode assembly;
- FIG. 18 is a perspective view of the distal end of the catheter including a further alternate embodiment of an electrode assembly;
- FIG. 19 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly;
- FIG. 20 is a perspective view of a distal end of a catheter including an alternate embodiment of an electrode assembly;
- FIG. 21 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly; and
- FIG. 22 is a perspective view of the distal end of a catheter including a further alternate embodiment of an electrode assembly.
- The following detailed description should be read with reference to the drawings, in which like elements in different drawings are numbered identically. The drawings which are not necessarily to scale, depict selected embodiments and are not intended to limit the scope of the invention.
- Examples of constructions, materials, dimensions, and manufacturing processes are provided for selected elements. All other elements employ that which is known to those of skill in the field of the invention. Those skilled in the art will recognize that many of the examples provided have suitable alternatives which may be utilized.
- FIGS. 1 and 2 are plan views of a
catheter 20 in accordance with the present invention. FIG. 1 is a plan view of adistal end 18 ofcatheter 20.Catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown) and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximatedistal end 18 ofcatheter 20.Insulator 32 includes a plurality ofinsulator lumens 34. - In FIG. 2 a distal portion of
catheter 20 is shown in partial cross-section. In FIG. 2, it can be appreciated thatelongate shaft 24 includes ashaft lumen 36.Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are disposed inlumen 36 ofelongate shaft 24. As is best shown in FIG. 2,electrode 30 ofcatheter 20 is generally formed frombent portion 42 ofconductor 40. As also shown in FIG. 2,insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 40 to pass throughinsulator 32. In a presently preferred embodiment,conductor 40 is adapted to be connected to a radio frequency generator. - One or
more retaining elements 50 are formed onconductor 40proximate insulator 32. In the embodiment of FIG. 2, retainingelements 50 have been created by forming two kinks inconductor 40. It will be understood that other embodiments of retainingelements 50 are possible without deviating from the spirit or scope of the present invention. It will also be understood that although two retaining elements are shown in FIG. 2, additional embodiments have been envisioned which utilize asingle retaining element 50. - As best seen in FIG. 2,
electrode 30 protrudes beyondinsulator 32 ofcatheter 20. The distance which electrode 30 protrudes is determined in part by the shape ofbent region 42 ofconductor 40. The distance which electrode 30 protrudes is carefully controlled during the manufacture ofcatheter 20. This helps to control the depth of the wounds which are created bycatheter 20 during a PMR procedure. During such aprocedure electrode 30 will proceed to penetrate the heart until insulator 32 contacts the heart tissue. As best seen in FIG. 1,insulator 32 includes twolanding zones 60 which extend away fromelectrode 30. In the embodiment of FIG. 1, the width oflanding zones 60 is substantially greater than the width ofelectrode 30. The relatively large area oflanding zones 60 assures that the travel ofelectrode 30 into the heart will stop when landingzones 60 contact the heart tissue. It is a desirable feature of this invention thatlanding zones 60 extend beyond the wound created in the heart tissue during a PMR procedure. This is because the wounded tissue is substantially softened, and it is possible for a PMR catheter to be pushed through soft, injured tissue. - The distance which electrode30 protrudes from landing
zones 60 and the relative surface areas of these elements are carefully selected to create a therapeutically effective wound while reducing the likelihood of unintentionally perforating the myocardium. A therapeutically effective wound generally must perforate the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating the myocardium is reduced when the depth of wound created is only enough to penetrate the endocardium. - By way of example, the dimensions below have been found effective in creating therapeutically effective wounds while reducing the likelihood that the myocardium will be punctured through to the epicardium.
- In a presently preferred embodiment the
distance electrode 30 protrudes from landingzones 60 is between about 0.005 and about 0.4 inches. In a presently most preferred embodiment thedistance electrode 30 protrudes from landingzones 60 is between about 0.010 and about 0.035 inches. - In a presently preferred embodiment, in accordance with FIG. 2, the diameter of
conductor 40 inbent portion 42 is between 0.003 and about 0.030 inches. In a presently most preferred embodiment, in accordance with FIG. 2, the diameter ofconductor 40 inbent portion 42 is between about 0.008 and about 0.012 inches. It should be understood that the diameter ofconductor 40 may vary along its length, andconductor 40 may include one or more tapered sections to optimize shaft support and flexibility. In a presently preferred embodiment,conductor 40 is about 70 inches long having a distal portion with a diameter of about 0.010 inches and a proximal portion with a diameter of about 0.022 inches. In this presently preferred embodiment,conductor 40 includes a transition portion which is about 8 inches long and which tapers from the diameter of the proximal portion to the diameter of the distal portion. - In a presently preferred embodiment in accordance with FIG. 2, the bend radius of
electrode 30 is between about 0.004 and about 0.1 inches. In the presently most preferred embodiment in accordance with FIG. 2, the bend radius ofelectrode 30 is between about 0.012 and about 0.023 inches. - In a presently preferred embodiment the width of
landing zones 60 extending from two sides ofelectrode 30 is between about 0.007 and about 0.050 inches. In a presently most preferred embodiment the width oflanding zones 60 extending from two sides ofelectrode 30 is between about 0.015 and about 0.030 inches. As described above, and shown in FIG. 1, there are two landingzones 60 extending away fromelectrode 30 in the embodiment of FIGS. 1 and 2. - Although breaking through the endocardium may be sufficient treatment for many patients, for some patients the physician may prefer to penetrate the myocardium with electrode30 a certain distance. As described previously, the depth which
electrode 30 penetrates heart tissue may be controlled by the geometry ofelectrode 30 andlanding zones 60. The distance which electrode 30 protrudes from landingzones 60 is carefully controlled during the manufacture ofcatheter 20. A number of models ofcatheter 20 may be supplied to a physician, each model being adapted to produce wounds of a specific depth. The depth of the wound created is influenced by the depth which the electrode penetrates the heart tissue. Other factors may influence the depth of wound created without deviating from the spirit or scope of the present invention. For example, the depth of wound created may be effected by the magnitude and frequency of the radiofrequency energy applied toelectrode 30. By way of a second example, the depth of wound produced may be effected by the length of time the electrode is energized. -
Conductor 40 andelectrode portion 30 may be comprised of stainless steel, Nitinol, or a number of other materials which are conductive and biocompatable. In a presently preferred embodiment,conductor 40 andelectrode portion 30 are comprised of Nitinol. Embodiments ofelectrode 30 have also been envisioned whereinelectrode 30 includes a radiopaque material. Examples of radiopaque material which may be included inelectrode 30 include: gold, platinum, silver, and tungsten. -
Insulator 32 may be formed from ceramic, glass, glass-ceramic, polytetrafluoroethylene (PTFE), polyimide, or a number of other materials which are non-conductive and biocompatible and/or thermally insulated and biocompatible. In a presently preferred embodiment,insulator 32 is formed from ceramic. Further embodiments ofinsulator 32 have been envisioned which include a radiopaque material. The radiopaque materials which may be suitable for inclusion in aninsulator 32 in some embodiments, include: gold, platinum, silver, tungsten, barium sulfide and bismuth oxide. In a presently preferred radiopaque embodiment ofinsulator 32, a radiopaque material is selectively applied to the outer diameter ofinsulator 32. A presently preferred radiopaque material is a platinum/iridium blend. - Although
conductor 40 in the embodiment of FIGS. 1 and 2 is circular in cross section, it should be understood that other cross-sectional shapes are possible without deviating from the spirit or scope of the invention. For example, the cross-sectional shape ofconductor 40 could be rectangular, square, triangular, oval, etc. - In a presently preferred embodiment,
elongate shaft 24 is comprised of polyether block amide (PEBA). Polyether block amide is commercially available from Atomchel Polymers of Birsdsboro Pa. under the trade name PEBAX.Elongate shaft 24 may be comprised of other materials without departing from the spirit of scope of this invention. Examples of materials which may be suitable in some applications include: polyethylene (PE), polypropylene (PP), polyvinylchloride (PVC), polyurethane, polyimide, and polytetrafluoroethylene (PTFE). - As described above, in a presently preferred embodiment,
insulator 32 andelongate shaft 24 are separate elements comprised of ceramic and PEBA respectively. However, it should be understood that these two elements could be combined into one element formed of one material without deviating from the spirit or scope of the present invention. In the embodiment of FIGS. 1 and 2,elongate shaft 24 has asingle lumen 36. It will be understood that embodiments of the present invention have been envisioned in which shaft 26 hasmultiple lumens 36. - During a PMR procedure,
catheter 20 is preferably advanced through the vasculature of a patient untildistal end 18 is proximate the endocardium of a patient's heart. The route taken bycatheter 20 will normally be by way of the femoral artery and the aorta to the left ventricle. - Those of skill in the art will appreciate that other routes may be taken without deviating from the spirit or scope of the present invention. For example,
catheter 20 may enter the right ventricle by way of the pulmonary vein or femoral vein. As a second example of an alternate route which may be taken bycatheter 20,catheter 20 may enter the right ventricle from the left ventricle by passing through the septal wall. As a third example of an alternate route which may be taken bycatheter 20,catheter 20 may enter the body at the carotid artery and reach the heart therethrough. - To facilitate the advancement of
catheter 20 through the vasculature of the patient,catheter 20 may include a slippery material disposed on the outer surfaces ofelongate shaft 24. Once inside the heart,distal end 18 ofcatheter 20 is positioned proximate the endocardium, preferably, such thatelectrode portion 30 is in contact with the endocardium.Electrode portion 30 may then be energized to form a wound. - Typically, an additional step in a method in accordance with the present invention is to identify areas of tissue within the patient's heart which are candidates for PMR. To facilitate ease of discussion, areas of tissue in the heart muscle may be generally classified healthy or hibernating. Healthy tissue is tissue which is well perfused with blood, and subsequently well supplied with oxygen. Hibernating tissue is tissue which is not currently contracting to assist in the pumping of blood. However, if hibernating tissue is adequately supplied with blood, it will once again begin contracting and contribute to the pumping of blood.
- A number of methods may be used to identify hibernating tissue. For example, contrast media may be injected into the coronary vessels to identify regions of the heart into which the contrast medium does not flow due to obstruction of the vessels into which the media was injected. In this case, the hibernating region will be identified by the lack of flow or abnormally low flow distally of the obstruction in the coronary vessel or vessels.
- A second method which may be used to identify hibernating regions of the heart involves injecting contrast media directly into the heart chambers. Hibernating tissue may then be identified by locating areas of generally poor wall motion of the heart chambers. When this method is selected, the contrast media may be delivered to the heart chambers via
catheter 20.Shaft lumen 36 andinsulator lumens 34 ofcatheter 20 provide a suitable channel for delivering contrast media from a location outside the patient's body todistal end 18 ofcatheter 20. - Once hibernating regions within the heart are identified, these regions may be targeted for PMR.
Electrode 30 will be positioned proximate the targeted heart tissue. In a presently preferred method, a contact detecting means in conjunction withelectrode 30 will be used to sense contact betweenelectrode 30 and heart tissue. This method is further detailed in a co-pending U.S. patent application Ser. No. ______, filed by the same assignee on even date herewith and entitled “Device and Method for Percutaneous Myocardial Revascularization.” - During a PMR procedure,
electrode 30 will proceed to penetrate the heart until landingzones 60 ofinsulator 32 contact the heart tissue. As described above, landingzones 60 have a relatively large surface area to assure that the depth of electrode penetration will be controlled. The depth of the wound is also influenced by the distance which electrode 30 protrudes from landingzones 60. As described above, this distance is carefully controlled during the manufacture ofcatheter 20. - As described above, the distance which electrode30 protrudes from landing
zones 60 and the relative surface areas of these elements are carefully selected to create a therapeutically effective wound while reducing the likelihood of unintentionally perforating the myocardium. Preferably, a therapeutically effective wound will perforate through the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating the myocardium to the epicardium is reduced when the depth of wound created is only enough to penetrate the endocardium. - Although breaking through the endocardium may be sufficient treatment for many patients, for some patients a physician may desire to penetrate the myocardium with electrode30 a certain distance. As described previously, the depth which
electrode 30 penetrates the heart tissue, may be controlled by the geometry ofelectrode 30 andlanding zones 60. A number of models ofcatheter 20 may be provided to a physician, each model being adapted to create wounds of a particular depth. The depth of wound created is influenced by the depth whichelectrode 30 penetrates heart tissue. Other factors may influence wound depth without deviating from the spirit and scope of the present invention. For example, the magnitude and frequency of the radiofrequency energy applied toelectrode 30 may effect the depth of wound created during a PMR procedure. By way of a second example, the length oftime electrode 30 is energized may effect the depth of wound created. - In a presently preferred method, a fluid under pressure is forced into the wound by way of
shaft lumen 36 andinsulator lumens 34. This fluid may include saline, radiopaque contrast media, a therapeutic agent, a caustic agent, or any combination of these. - The formation of the wound may be enhanced by collateral damage to the myocardium induced by directing this pressurized fluid into the wound site. The impact of the pressurized fluid causes vessels, capillaries, and sinuses to rupture. By creating this collateral damage, the number of wounds which must be made during a PMR procedure can be substantially reduced. Injecting a fluid including a radiopaque contrast media into the wound serves to create a radiopaque marker of the treatment site. Injecting a fluid, including a therapeutic agent, serves to promote angiogenisis.
- Forcing fluid under pressure into the wound may be used to create collateral damage. Collateral damage is created when vessels, capillaries, and sinuses within the myocardium are ruptured. Thus collateral damage will increase the healing response of the body. The fluid under pressure may be forced into the wound while
electrode 30 is energized or during a time whenelectrode 30 is not energized. In either case, the distal end ofcatheter 20 is positioned proximate the wound. Becauseelectrode 30 was used to create the wound,catheter 20 is in an ideal position to inject fluid into the wound. If a separate catheter was used to deliver fluid, the distal end of that catheter would need to be positioned over the wound. - A PMR system for use with
catheter 20 may include a means for controlling the flow of fluid throughcatheter 20. In one embodiment of the invention, the means for controlling would direct fluid to be injected into the wound immediately after each spark. In a second envisioned embodiment of the present invention, a PMR system for use withcatheter 20 would include a foot pedal capable of activating the means for controlling fluid flow, and the means for energizingelectrode 30. In this embodiment of the present invention, fluid would flow from the distal end ofcatheter 20 whileelectrode 30 was energized. Several other embodiments of the means for controlling fluid flow are possible without deviating from the spirit or scope of the present invention. For example, fluid may be delivered a set time after energy is delivered. - A second benefit of collateral damage is that it may reduce the wound depth needed to create clinically effective results. The depth of the wound may be limited so that the wound just passes through the endocardium. Once the endocardium is perforated, pressure from infused fluid may be used to rupture myocardial vessels, capillaries and sinuses without further ablation or removal of tissue. As discussed previously, limiting the depth of ablation reduces the likelihood of unintentional myocardial perforation.
- Those with skill in the art will appreciate that
catheter 20 may also be used in procedures where collateral damage is deemed undesirable. Collateral damage may be avoided by not delivering fluid throughcatheter 20, or by delivering fluid throughcatheter 20 at a relatively low pressure. In addition to promoting increased blood flow, it is also believed that PMR improves a patient's condition through denervation. Specifically, the PMR induced wounds result in elimination of nerve endings which were previously sending pain signals to the brain as a result of hibernating tissue. - As described previously, increased blood flow to the myocardium is caused in part by the healing response to wound formation during PMR. Specifically, the formation of new vessels or capillaries is believed to occur in response to a newly created wound. The revascularization of myocardial tissue may be promoted by delivering a therapeutic agent to the wound area. Examples, of therapeutic agents include growth factors, drugs and caustic agents. In one embodiment of the present invention, the PMR procedure includes the step of delivering a therapeutic agent to the wound site via
catheter 20.Shaft lumen 36 andinsulator lumens 34 ofcatheter 20 provide a suitable channel for delivering a therapeutic agent to the wound site from a location outside the patient's body. - Fluids delivered via
catheter 20 during a PMR procedure may provide additional benefits. For example, fluid delivered viacatheter 20 may serve to coolelectrode 30 during a PMR procedure. As a second example, fluid delivered viacatheter 20 may serve to remove debris from the wound. It should be understood that steps may be omitted from the method described above, or the order of the steps may be changed without deviating from the spirit or scope of the present invention. - Those with skill in the art will recognize that
catheter 20 may be used with bipolar or mono-polar PMR techniques. In a mono-polar PMR procedure, a return or neutral electrode is generally attached to the exterior of the patient. In a bi-polar PMR technique, a return or neutral electrode is positioned in close proximity todistal end 18 ofcatheter 20. For example, a tubular return electrode may be disposed on the outer surface ofcatheter 20 proximate itsdistal end 18. - A bi-polar embodiment of the present invention is illustrated if FIG. 3. FIG. 3 is a plan view of a
distal portion 22 of acatheter 20. As in the embodiment of FIGS. 1 and 2,catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and areturn electrode 332 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 3,
elongate shaft 24 includes alumen 36.Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are disposed inlumen 36.Electrode 30 ofcatheter 20 is generally formed frombent portion 42 ofconductor 40.Return electrode 332 defines twoholes 48. Twosleeves 302 are disposed inside holes 48.First leg 44 andsecond leg 46 pass throughsleeves 302. In the embodiment of FIG. 3,return electrode 332 is comprised of a conductive material allowing it to serve as a return electrode in a bi-polar PMR configuration.Sleeves 302 are comprised of a non-conductive material, and serve to insulateconductor 40 fromreturn electrode 332. Areturn conductor 304 is coupled to returnelectrode 332.Return conductor 332 is suitably insulated so that it will not make electrical contact withconductor 40. In one envisioned embodiment of the present invention,return conductor 332 is disposed in a separate lumen ofelongate shaft 24. - FIG. 4 is a plan view of a
distal portion 22 of acatheter 20 in accordance with a bi-polar embodiment of the present invention. As in the embodiment of FIGS. 1 and 2,catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 4,
elongate shaft 24 includes alumen 36.Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are disposed inlumen 36.Electrode 30 ofcatheter 20 is generally formed frombent portion 42 ofconductor 40.Insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 40 to pass throughinsulator 32. - In the embodiment of FIG. 4, a
return electrode 332 is disposed about the outer surface ofinsulator 32.Return electrode 332 is comprised of a conductive material allowing it to serve as a return electrode in a bi-polar PMR configuration. Areturn conductor 304 is coupled to returnelectrode 332.Return conductor 332 is suitably insulated so that it will not make electrical contact withconductor 40. In one envisioned embodiment of the present invention,return conductor 332 is disposed in a separate lumen ofelongate shaft 24. As shown in FIG. 4, return electrode 332 protrudes beyond the distal end ofelongate shaft 24. - FIG. 5 is a plan view of a
distal portion 22 of acatheter 20 in accordance with a bi-polar embodiment of the present invention. As in the embodiment of FIGS. 1 and 2,catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - In the embodiment of FIG. 5,
elongate shaft 24 is comprised of an outertubular member 312 and an innertubular member 310 having alumen 36. Aconductive coating 314 is disposed on the outer diameter of innertubular member 310. Outertubular member 312 is comprised of a non-conductive material and generally overlaysconductive coating 314. In one embodiment outertubular member 312 is comprised of shrink tubing. In a second embodiment outertubular member 312 is comprised of a nonconductive coating. A portion ofconductive coating 314 proximatedistal end 18 is not covered by outertubular member 312. Embodiments of the present invention have been envisioned in which exposed portions ofconductive coating 314 act as a return electrode. In the embodiment of FIG. 5, areturn electrode 316 is disposed about and electrically coupled toconductive coating 314. In a presently preferred embodiment,return electrode 316 is comprised of a material which is conductive and radiopaque. Examples of suitable materials include gold, platinum, silver, and tungsten. - In the embodiment of FIG. 5,
conductive coating 314 acts as an electrical conductorcoupling return electrode 316 to the radio frequency generator used in a PMR procedure.Catheter 20 of FIG. 5 also includes anelectrode 30 generally formed frombent portion 42 ofconductor 40. In one embodiment of the present invention,conductor 40 is electrically coupled to a radio frequency generator (not shown) by a cable (not shown). In a presently preferred embodiment,conductor 40 is directly attached to the cable. - FIG. 6 is a plan view of a
distal portion 22 of acatheter 20 in accordance with one embodiment of the present invention. As in the embodiment of FIGS. 1 and 2,catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and ainsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 6,
elongate shaft 24 includes alumen 36.Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are disposed inlumen 36.Electrode 30 ofcatheter 20 is generally formed frombent portion 42 ofconductor 40.Insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 40 to pass throughinsulator 32. Agroove 340 is disposed on the outer diameter ofinsulator 32. A band 342 is disposed ingroove 340. In a presently preferred embodiment, band 342 is comprised of a radiopaque material. When radiographic equipment is used in conjunction withcatheter 20, band 342 aids the physician in locatingdistal end 18 ofcatheter 20. Band 342 may be comprised of a number of radiopaque materials including gold, platinum, silver, tungsten, barium sulfate, and bismuth oxide. In a presently preferred embodiment, band 342 is a platinum/iridium blend. - Referring now to FIGS. 7 and 8, which illustrate an additional embodiment of
catheter 20. FIG. 8 is a plan view ofdistal portion 22 ofcatheter 20 shown in partial cross section. FIG. 7 is a plan view ofdistal end 18 of the embodiment ofcatheter 20 shown in FIG. 8. As in the previous embodiment,catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), adistal portion 22, and adistal end 18. Anelectrode portion 30 and aninsulator 32 are disposed proximatedistal end 18 ofcatheter 20. As best seen in FIG. 7,insulator 32 includes twolanding zones 60 which extend away fromelectrode 30. - As best shown in FIG. 8,
elongate catheter 20 includes aconductor 140 having abent portion 142, afirst leg 144, and asecond leg 146.Conductor 140 also defines alumen 200 and twoholes 202 which are in fluid communication withlumen 200.Holes 202 inconductor 40 are shown most clearly in FIG. 7. -
First leg 144 andsecond leg 146 are disposed inlumen 36 ofelongate shaft 24.Electrode 30 is generally formed frombent portion 142 ofconductor 140. As best shown in FIG. 8,insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 140 to pass throughinsulator 32. - A retaining
element 150 is formed onconductor 140proximate insulator 32. In the embodiment of FIG. 8, retainingelement 150 has been created by forming aweld bead 204 onconductor 140..Weld bead 204 may be formed using a number of manufacturing processes. For example, welding, solder, and brazing are all suitable processes of creatingweld bead 204. It will be understood that other embodiments of retainingelement 150 are possible without deviating from the spirit or scope of the present invention. In the embodiment of FIGS. 3 and 4,weld bead 204 also serves the function of sealing the end oflumen 200. - As in the previous embodiment,
electrode 30 protrudes beyondinsulator 32 ofcatheter 20. The distance which electrode 30 protrudes is determined in part by the shape ofbent region 142 ofconductor 140. The distance which electrode 30 protrudes is carefully controlled during the manufacture ofcatheter 20. This helps to control the depth of the wounds created bycatheter 20 during a PMR procedure. During such aprocedure electrode 30 will proceed to penetrate the heart until insulator 32 contacts the heart tissue. - As best seen in FIG. 7,
insulator 32 includes twolanding zones 60 which extend away fromelectrode 30. The width oflanding zones 60 is substantially greater than the width ofelectrode 30 in FIG. 7. The relatively large area oflanding zones 60 assure that the travel ofelectrode 30 into the heart tissue will stop when landingzones 60 contact the heart tissue. It is a desirable feature of this invention thatlanding zones 60 generally extend beyond the wound created in the heart tissue created during a PMR procedure. This is because the wounded tissue is substantially softened, and it is possible for a PMR catheter to be pushed through soft, injured tissue. - The distance which electrode30 protrudes from landing
zones 60 and the relative surface areas of these elements are carefully selected to create a therapeutically effective wound while reducing the likelihood of unintentionally perforating the myocardium. Preferably, a therapeutically effective wound will at a minimum perforate through the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating through the myocardium to the epicardium is reduced when the depth of wound created is only enough to penetrate the endocardium. - During a PMR procedure,
catheter 20 is preferably advanced through the vasculature of a patient untildistal end 18 is proximate the endocardium of the patient's heart. The route taken bycatheter 20 will normally be by way of the femoral artery and the aorta to the left ventricle. Those with skill in the art will appreciate that other routes may be taken bycatheter 20 without deviating from the spirit or scope of the present invention. For example, the right ventricle may be accessed via the pulmonary vein or the femoral vein. By way of a second example, the septal approach may be used. In a septal approach, the distal end ofcatheter 20 first enters one ventricle (the left or the right). A PMR procedure may be performed in that ventricle. The distal end ofcatheter 20 may then enter the other ventricle by passing through the septal wall. A third example of a route which may be taken bycatheter 20 is a route via the carotid artery. - To facilitate the advancement of
catheter 20 through the vasculature of the patient,catheter 20 may include a slippery material disposed on the outer surfaces ofelongate shaft 24. Once inside the heart,distal end 18 ofcatheter 20 is positioned proximate the endocardium, preferably, such thatelectrode portion 30 is in contact with the endocardium. Contact between the endocardium andelectrode 30 may be detected electronically. A method is further detailed in co-pending U.S. patent application Ser. No. ______, filed by the same assignee on even date herewith and entitled “Device and Method for Percutaneous Myocardial Revascularization.”. The disclosure of this co-pending application is hereby incorporated by reference into the present application. - An additional method which may be used to determine the location of
electrode 30 is through radiographic techniques. The use of radiographic techniques may be enhanced by selectively incorporating radiopaque material intocatheter 20. In one embodiment of the present invention, a radiopaque material is disposed about the outer diameter ofinsulator 32. The radiopaque material may be comprised of a band of metal. Materials which may be suitable for this marker band include: gold, platinum, silver, and tungsten. A radiopaque material may also be included inelectrode 30 and/orinsulator 32. - Typically, an additional step in a method in accordance with the present invention is to identify areas of tissue within the patient's heart which are candidates for PMR. To facilitate ease of discussion, areas of tissue in the heart muscle may be generally classified healthy or hibernating. Healthy tissue is tissue which is well perfused with blood, and subsequently well supplied with oxygen. Hibernating tissue is tissue which is not currently contracting to assist in the pumping of blood. However, if hibernating tissue is adequately supplied with blood, it will once again begin contracting and contribute to the pumping of blood.
- A number of methods may be used to identify hibernating tissue. For example, contrast media may be injected into the coronary vessels to identify regions of the heart into which the contrast medium does not flow due to obstruction of the vessels into which the media was injected. In this case, the hibernating region will be identified by the lack of flow or abnormally low flow distally of the obstruction in the coronary vessel or vessels.
- A second method which may be used to identify hibernating regions of the heart involves injecting contrast media directly into the heart chambers. Hibernating tissue may then be identified by locating areas of generally poor wall motion of the heart chambers. When this method is selected, the contrast media may be delivered to the heart chambers via
catheter 20.Lumen 200 andholes 202 ofconductor 140 provide a channel for delivering contrast media from a location outside the patients body todistal end 18 ofcatheter 20. - Once hibernating regions within the heart area identified, these regions are candidates for PMR. During the PMR procedure,
electrode 30 will proceed to penetrate the heart until landingzones 60 ofinsulator 32 contact the heart tissue. As described above, landingzones 60 have a relatively large surface area to assure that the depth of the wound will be controlled. The depth of the wound is also controlled by the distance which electrode 30 protrudes from landingzones 60. As described above, this distance is carefully controlled during the manufacture ofcatheter 20. - As described above, the distance which electrode30 protrudes from landing
zones 60 and the relative surface areas of these elements are carefully selected to create a therapeutically effective wound while reducing the likelihood of unintentionally perforating the myocardium. Preferably, a therapeutically effective wound generally will, at a minimum, perforate through the endocardium and damage blood vessels and capillaries in the myocardium. The likelihood of unintentionally perforating through the myocardium to the epicardium is reduced when the depth of wound created is only enough to penetrate the endocardium. - In a presently preferred method, a fluid under pressure is forced into the wound through
lumen 200 andholes 202 ofconductor 140. This fluid may include saline, contrast media, a therapeutic agent, a caustic agent, or any combination of these. By forcing fluid under pressure into the wound, vessels, capillaries, and sinuses in the myocardium will be collaterally damaged within an area proximate the wound. This collateral damage will increase the healing response by angiogenesis. The fluid under pressure may be forced into the wound whileelectrode 30 is energized, or during a time whenelectrode 30 is not energized. - The formation of the wound may be enhanced by collateral damage to the myocardium induced by directing this pressurized fluid into the wound site. The impact of the pressurized fluid causes vessels, capillaries, and sinuses to rupture. By creating this collateral damage, the number of wounds which need to be made during a PMR procedure may be substantially reduced.
- A second benefit of collateral damage is that it may reduce the wound depth needed to create clinically effective results. The depth of the wound may be limited so that the wound just passes through the endocardium. Once the endocardium is perforated, pressure from infused fluid may be used to rupture the myocardial vessels, capillaries and sinuses without further ablation or removal of tissue. Limiting the depth of ablation reduces the likelihood of unintentional myocardial perforation. In addition, the injection of a fluid containing a radiopaque contrast solution creates a fluoroscopic marker of the treatment location.
- An additional benefit of having
holes 202 disposed at the distal end ofcatheter 20 is that they permit the fluid to be injected into the wound immediately after it is created. - This eliminates the need to withdraw
catheter 20 and position a second catheter to deliver fluid to the wound. - As described previously, increased blood flow to the myocardium is caused in part by the healing response to wound formation during PMR. Specifically, the formation of new vessels or capillaries is believed to occur in response to a newly created wound. The revascularization of myocardial tissue may be promoted by delivering a therapeutic agent to the wound area. Examples, of therapeutic agents include growth factors and drugs. In one embodiment of the present invention, the PMR procedure includes the step of delivering a therapeutic agent though
lumen 200 andholes 202 ofconductor 140. - In a presently preferred method, a fluid is delivered via
catheter 20 to the patient proximate the wound. This fluid may include saline, radiopaque contrast media, a therapeutic agent, a caustic agent, or any combination of these. Injecting a fluid including a radiopaque contrast media acts to create a radiopaque marker of the treatment site. Injecting a fluid into a wound which includes a therapeutic agent acts to enhance the angiogenisis response of the body. An embodiment of the present invention has been envisioned where the same control means which enables radiofrequency energy to energizeelectrode 30 may be used to enable fluid to be injected into the wound from the distal end ofcatheter 20. In a presently preferred embodiment, the control means of the PMR system directs fluid to be injected into the wound immediately after each spark. Fluids delivered viacatheter 20 during a PMR procedure may provide additional benefits. For example, fluid delivered vialumen 200 ofconductor 140 may serve to coolelectrode 30 during a PMR procedure. As a second example, fluid delivered viacatheter 20 may serve to remove debris from the wound. It should be understood that steps may be omitted from the method described above, or the order of the steps may be changed without deviating from the spirit or scope of the present invention. - FIG. 9 is a plan view of a
distal portion 22 of acatheter 20 in accordance with an alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 9,
elongate shaft 24 includes twolumens Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are disposed inlumens Electrode 30 ofcatheter 20 is general formed frombent portion 42 ofconductor 40.Insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 40 to pass throughinsulator 32.Insulator 32 defines additional holes (not shown) which allow fluid to pass therethrough. - Two retaining
elements 50 are located onconductor 40proximate insulator 32. In the embodiment of FIG. 9, each retainingelement 50 is asleeve surrounding conductor 40. Each retainingelement 50 has been fixed toconductor 40 with a crimping process. Retainingelements 50 assist in maintaining the position ofbent portion 42; preventing it from moving before, or during a PMR procedure.Insulator 32, acting in conjunction with retainingelements 50, supportsbent portion 42 ofconductor 40, preventing it from being deformed during a PMR procedure. - FIG. 10 is a plan view of a
distal portion 22 of acatheter 20 in accordance with an alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. -
Elongate shaft 24 includes twolumens Catheter 20 includes aconductor 640 having abent portion 642, afirst portion 652, and asecond portion 654. As shown in FIG. 10, the outer diameter ofsecond portion 654 is smaller than the outer diameter offirst portion 652.Conductor 640 includes astep 650 proximate the intersection betweenfirst portion 652 andsecond portion 654. -
First portion 652 ofconductor 640 is substantially disposed inlumen 36A ofelongate shaft 24.Second portion 654 ofconductor 640 passes throughinsulator 32 via twoholes 48. The remaining portion ofsecond portion 654 is disposed inlumen 36B ofelongate shaft 24. Abent portion 642 ofconductor 640 extends beyondinsulator 32; anelectrode 30 is general formed bybent portion 642. - A retaining
element 50 is located onsecond portion 654proximate insulator 32. In the embodiment of FIG. 10, retainingelement 50 is asleeve surrounding conductor 640. A number of processes may be used to fix retainingelement 50 ontoconductor 640. For example, there may be an interference fit between the sleeve andconductor 640. Other examples of acceptable retention methods include soldering, brazing, welding, crimping, and adhering with an adhesive. Retainingelement 50 and step 650 assist in maintaining the position ofbent portion 642; preventing it from moving before, or during a PMR procedure.Insulator 32, acting in conjunction with retainingelement 50, supportsbent portion 642 ofconductor 640, preventing it from being deformed during a PMR procedure. - FIG. 11 is a plan view of a
distal portion 22 of acatheter 20 in accordance with an alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 11,
elongate shaft 24 includes alumen 36.Catheter 20 includes aconductor 740 having a bent portion 742, afirst leg 744, and asecond leg 746.First leg 744 andsecond leg 746 are substantially disposed inlumen 36.Electrode 30 ofcatheter 20 is general formed by bent portion 742 ofconductor 740.Insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 740 to pass throughinsulator 32. - A
bond 750 is formed betweenfirst leg 744 andsecond leg 746 ofconductor 740. A number of process may be used to createbond 750. For example,bond 750 may be created by applying an adhesive betweenfirst leg 744 andsecond leg 746. Other techniques which may be used to fabricatebond 750 include welding, brazing, and soldering. - FIG. 12 is a plan view of a
distal portion 22 of acatheter 20 in accordance with an alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 12,
elongate shaft 24 includes twolumens Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are substantially disposed inlumens Electrode 30 ofcatheter 20 is general formed frombent portion 42 ofconductor 40.Insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 40 to pass throughinsulator 32. - Two retaining
elements 50 are located onconductor 40proximate insulator 32. In the embodiment of FIG. 12, each retainingelement 50 is formed from material ofconductor 40 which has been displaced to create a localized area with a greater width. A crimping or staking process may be used to create deformations of this type inconductor 40. - Retaining
elements 50 assist in maintaining the position ofbent portion 42; preventing it from moving before, or during a PMR procedure.Insulator 32 acting in conjunction with retainingelements 50 supports bentportion 42 ofconductor 40, preventing it from being deformed during a PMR procedure. - FIG. 13 is a plan view of a
distal portion 22 of acatheter 20 in accordance with an alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 13,
elongate shaft 24 includes twolumens Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are substantially disposed inlumens Electrode 30 ofcatheter 20 is general formed frombent portion 42 ofconductor 40.Insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 40 to pass throughinsulator 32. -
Conductor 40 is fixed toinsulator 32 by twoadhesive bonds bent portion 42 from moving before, or during a PMR procedure.Insulator 32 acting in conjunction withadhesive bonds bent portion 42 ofconductor 40, preventing it from being deformed during a PMR procedure. - FIG. 14 is a plan view of a
distal portion 22 of acatheter 20 in accordance with an alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22. Anelectrode portion 30 and aninsulator 32 are disposed proximate adistal end 18 ofcatheter 20. - As shown in FIG. 14,
elongate shaft 24 includes twolumens Catheter 20 includes aconductor 40 having abent portion 42, afirst leg 44, and asecond leg 46.First leg 44 andsecond leg 46 are substantially disposed inlumens Electrode 30 ofcatheter 20 is general formed frombent portion 42 ofconductor 40.Insulator 32 defines twoholes 48 which are adapted to allowlegs conductor 40 to pass throughinsulator 32. - In the embodiment of FIG. 14,
lumens elongate shaft 24 are substantially filled withpotting material 950.Potting material 950 serves to fix the location ofconductor 30 relative toinsulator 32 andelongate shaft 24.Potting material 950 may be comprised of a number of materials. Examples of suitable materials include silicone rubber and urethane.Catheter 20 andinsulator 32 may include additional lumens (not shown in FIG. 14) which allow a fluid to be conducted from proximal end 26 ofcatheter 20 todistal end 18 ofcatheter 20. - FIG. 15 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 15,electrode 930 is comprised of aconductor 932 which is generally cylindrical in shape. During a PMR procedure in accordance with a presently preferred embodiment of the present invention,electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - FIG. 16 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an additional alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 16,electrode 930 is comprised of twoconductors Conductors electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - FIG. 17 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an additional alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 17,electrode 930 is comprised of twoconductors Conductors electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - FIG. 18 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an additional alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 18,electrode 930 is comprised of astraight portion 942 and acurved portion 944. During a PMR procedure in accordance with a presently preferred embodiment of the present invention,electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - FIG. 19 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an additional alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 19,electrode 930 is comprised of astraight portion 946 and aring portion 948. During a PMR procedure in accordance with a presently preferred embodiment of the present invention,electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - FIG. 20 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an additional alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 20,electrode 930 includes twostraight portions distal end 910 ofelongate shaft 24.Electrode 930 also includes a hoop portion 956 having two ends 958. One end 958 of hoop 956 is joined to the distal end ofstraight portion 952. The other end 958 of hoop 956 is joined to the distal end ofstraight portion 954. During a PMR procedure in accordance with a presently preferred embodiment of the present invention,electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - FIG. 21 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an additional alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 21,electrode 930 includes twostraight portions distal end 910 ofelongate shaft 24.Electrode 930 also includes an interconnecting portion 966 having two ends 968. One end 968 of interconnecting portion 966 is joined to the distal end ofstraight portion 962. The other end 968 of interconnecting portion 966 is joined to the distal end ofstraight portion 964. In the embodiment of FIG. 21, interconnecting portion 966 is generally “U” shaped. During a PMR procedure in accordance with a presently preferred embodiment of the present invention,electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - FIG. 22 is a perspective view of a
distal portion 22 of acatheter 20 in accordance with an additional alternate embodiment of the present invention. As in theprevious embodiments catheter 20 includes anelongate shaft 24, a proximal end 26 (not shown), and adistal portion 22.Elongate shaft 24 includes adistal end 910. Anelectrode 930 projects fromdistal end 910 ofelongate shaft 24. In the embodiment of FIG. 22,electrode 930 includes twostraight portions distal end 910 ofelongate shaft 24.Electrode 930 also includes an interconnectingportion 976 having two ends 978. One end 978 of interconnectingportion 976 is joined to the distal end ofstraight portion 972. The other end 978 of interconnectingportion 976 is joined to the distal end ofstraight portion 974. In the embodiment of FIG. 22, interconnectingportion 976 is generally “S” shaped. During a PMR procedure in accordance with a presently preferred embodiment of the present invention,electrode 930 is energized with radio frequency energy causing it to create a wound. During wound formation,electrode 930 penetrates the tissue of the heart.Electrode 930 continues penetrating heart tissue untildistal end 910 ofelongate shaft 24 contacts the surface of the heart tissue. - Having thus described the preferred embodiments of the present invention, those of skill in the art will readily appreciate that yet other embodiments may be made and used within the scope of the claims hereto attached.
- A PMR method in accordance with the present invention, may include the step of delivering a fluid to the wound site via catheter102. Contact detecting means 706 may be used to verify that
distal end 18 is proximate myocardial tissue before delivering the fluid. This fluid may include saline, radiopaque contrast media, a therapeutic agent, a caustic agent, or any combination of these. Injecting a fluid including a radiopaque contrast media into the wound serves to create a radiopaque marker of a treatment site. Injecting a fluid, including a therapeutic agent, serves to promote angiogenisis. The formation of the wound may also be enhanced by collateral damage to the myocardium induced by directing pressurized fluid into the wound site. The impact of the pressurized fluid causes vessels, capillaries, and sinuses to rupture. - Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The inventions's scope is, of course, defined in the language in which the appended claims are expressed.
Claims (40)
1. A catheter assembly, comprising:
an elongate shaft having a proximal end, and a distal end;
a lumen defined by the elongate shaft and extending through at least a portion thereof;
a conductor including a bent portion, a first leg portion, and a second leg portion;
wherein the first and second leg portions are disposed in the lumen of the catheter; and
the bent portion of the conductor protruding from the distal end of the elongate shaft;
2. The catheter assembly of , further including a conductor lumen defined by the conductor.
claim 1
3. The catheter assembly of , further including a hole defined by the conductor and in fluid communication with the conductor lumen.
claim 2
4. The catheter assembly of , further including at least one retaining element disposed on the conductor proximate the distal end of the elongate shaft.
claim 1
5. The catheter assembly of , wherein at least one retaining element is a crimp.
claim 4
6. The catheter assembly of , wherein at least one retaining element is a weld bead.
claim 4
7. The catheter assembly of , wherein at least one retaining element is a sleeve.
claim 4
8. The catheter assembly of , wherein at least one retaining element is a kink.
claim 4
9. The catheter assembly of , wherein at least one retaining element is a step.
claim 4
10. The catheter assembly of , wherein at least one retaining element is a filler.
claim 4
11. The catheter assembly of , wherein at least one retaining element is a localized area of greater width.
claim 4
12. The catheter assembly of , wherein the conductor includes at least one tapered section.
claim 1
13. The catheter assembly of , wherein the conductor is comprised of stainless steel.
claim 1
14. The catheter assembly of , wherein the conductor is comprised of Nitinol.
claim 1
15. The catheter assembly of , wherein the bent portion of the conductor is generally U shaped.
claim 1
16. The catheter assembly of , further comprising a radio frequency generator connected to the conductor.
claim 1
17. A catheter assembly, comprising:
an elongate shaft having a proximal end, and a distal end;
a lumen defined by the elongate shaft and extending through at least a portion thereof;
an insulator fixedly attached to the elongate shaft proximate it's distal end;
the insulator defining at least one hole;
a conductor including a bent portion and at least one leg portion;
the leg portion of the conductor passing through the hole of the insulator and being disposed in the lumen of the catheter; and
the bent portion of the conductor protruding from the distal end of the elongate shaft;
18. The catheter assembly of , further including a conductor lumen defined by the conductor.
claim 17
19. The catheter assembly of , further including a hole defined by the conductor and in fluid communication with the conductor lumen.
claim 18
20. The catheter assembly of , further including at least one retaining element disposed on the conductor proximate the insulator.
claim 17
21. The catheter assembly of , wherein at least one retaining element is a crimp.
claim 20
22. The catheter assembly of , wherein at least one retaining element is a weld bead.
claim 20
23. The catheter assembly of , wherein at least one retaining element is a sleeve.
claim 20
24. The catheter assembly of , wherein at least one retaining element is a kink.
claim 20
25. The catheter assembly of , wherein at least one retaining element is a step.
claim 14
26. The catheter assembly of , wherein at least one retaining element is a filler.
claim 14
27. The catheter assembly of , wherein at least one retaining element is a localized area of greater width.
claim 14
28. The catheter assembly of , wherein the conductor includes at least one tapered portion.
claim 17
29. The catheter assembly of , wherein the conductor is comprised of stainless steel.
claim 17
30. The catheter assembly of , wherein the conductor is comprised of Nitinol.
claim 17
31. The catheter assembly of , further comprising a radio frequency generator connected to the conductor.
claim 17
32. The catheter assembly of , wherein the bent portion of the conductor is generally U shaped.
claim 17
33. A method of performing PMR, comprising the steps of:
providing a catheter including an elongate shaft having a proximal end, a distal end;
a conductor including a bent portion, a first leg portion, and a second leg portion;
the conductor defining a conductor lumen and the bent portion of the conductor protruding from the distal end of the elongate shaft;
positioning the distal end of the catheter proximate the endocardium of a patient's heart; and
energizing the conductor with radio frequency energy.
34. The method of , wherein the elongate shaft includes landing zones proximate its distal end.
claim 33
35. The method of , wherein the landing zones are adapted to halt the travel of the conductor into heart tissue.
claim 34
36. The method of , further including the step of delivering a pressurized fluid through the distal end of the catheter.
claim 33
37. The method of , wherein the fluid includes a therapeutic agent.
claim 36
38. The method of , wherein the fluid includes a contrast media.
claim 36
39. The method of , wherein the fluid includes saline.
claim 36
40. The method of , wherein the therapeutic agent is a growth factor.
claim 37
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/814,314 US20010049523A1 (en) | 1999-02-24 | 2001-03-21 | PMR catheter |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/256,831 US6217575B1 (en) | 1999-02-24 | 1999-02-24 | PMR catheter |
US09/814,314 US20010049523A1 (en) | 1999-02-24 | 2001-03-21 | PMR catheter |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/256,831 Continuation US6217575B1 (en) | 1999-02-24 | 1999-02-24 | PMR catheter |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010049523A1 true US20010049523A1 (en) | 2001-12-06 |
Family
ID=22973765
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/256,831 Expired - Lifetime US6217575B1 (en) | 1999-02-24 | 1999-02-24 | PMR catheter |
US09/814,314 Abandoned US20010049523A1 (en) | 1999-02-24 | 2001-03-21 | PMR catheter |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/256,831 Expired - Lifetime US6217575B1 (en) | 1999-02-24 | 1999-02-24 | PMR catheter |
Country Status (5)
Country | Link |
---|---|
US (2) | US6217575B1 (en) |
EP (1) | EP1154726A1 (en) |
JP (1) | JP2002537059A (en) |
CA (1) | CA2362921A1 (en) |
WO (1) | WO2000049956A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030137008A1 (en) * | 2000-03-28 | 2003-07-24 | Hidetoshi Nozaki | Solid state imaging device having a photodiode and a MOSFET and method of manufacturing the same |
US20040267337A1 (en) * | 2003-06-30 | 2004-12-30 | Cardiac Pacemakers, Inc. | Method and apparatus for diverting blood flow during ablation procedures |
WO2008063506A2 (en) * | 2006-11-13 | 2008-05-29 | Co-Repair, Inc. | Method for the treatment of heart tissue |
US7704222B2 (en) | 1998-09-10 | 2010-04-27 | Jenavalve Technology, Inc. | Methods and conduits for flowing blood from a heart chamber to a blood vessel |
US8285393B2 (en) | 1999-04-16 | 2012-10-09 | Laufer Michael D | Device for shaping infarcted heart tissue and method of using the device |
US8353907B2 (en) | 2007-12-21 | 2013-01-15 | Atricure, Inc. | Ablation device with internally cooled electrodes |
US8998892B2 (en) | 2007-12-21 | 2015-04-07 | Atricure, Inc. | Ablation device with cooled electrodes and methods of use |
US10993805B2 (en) | 2008-02-26 | 2021-05-04 | Jenavalve Technology, Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US11065138B2 (en) | 2016-05-13 | 2021-07-20 | Jenavalve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system |
US11185405B2 (en) | 2013-08-30 | 2021-11-30 | Jenavalve Technology, Inc. | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
US11199940B1 (en) * | 2020-04-21 | 2021-12-14 | Corel Corporation | Three-dimensional operations based on planar projections in graphic user interfaces |
US11197754B2 (en) | 2017-01-27 | 2021-12-14 | Jenavalve Technology, Inc. | Heart valve mimicry |
US11337800B2 (en) | 2015-05-01 | 2022-05-24 | Jenavalve Technology, Inc. | Device and method with reduced pacemaker rate in heart valve replacement |
US11357624B2 (en) | 2007-04-13 | 2022-06-14 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
US11517431B2 (en) | 2005-01-20 | 2022-12-06 | Jenavalve Technology, Inc. | Catheter system for implantation of prosthetic heart valves |
US11564794B2 (en) | 2008-02-26 | 2023-01-31 | Jenavalve Technology, Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US11589981B2 (en) | 2010-05-25 | 2023-02-28 | Jenavalve Technology, Inc. | Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297145B2 (en) | 1997-10-23 | 2007-11-20 | Arthrocare Corporation | Bipolar electrosurgical clamp for removing and modifying tissue |
US6770071B2 (en) * | 1995-06-07 | 2004-08-03 | Arthrocare Corporation | Bladed electrosurgical probe |
US5697882A (en) | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
US6159194A (en) * | 1992-01-07 | 2000-12-12 | Arthrocare Corporation | System and method for electrosurgical tissue contraction |
US6837887B2 (en) * | 1995-06-07 | 2005-01-04 | Arthrocare Corporation | Articulated electrosurgical probe and methods |
US7276063B2 (en) * | 1998-08-11 | 2007-10-02 | Arthrocare Corporation | Instrument for electrosurgical tissue treatment |
US6641610B2 (en) * | 1998-09-10 | 2003-11-04 | Percardia, Inc. | Valve designs for left ventricular conduits |
AU6384699A (en) * | 1998-09-10 | 2000-04-03 | Percardia, Inc. | Tmr shunt |
US6290728B1 (en) * | 1998-09-10 | 2001-09-18 | Percardia, Inc. | Designs for left ventricular conduit |
US6261304B1 (en) | 1998-09-10 | 2001-07-17 | Percardia, Inc. | Delivery methods for left ventricular conduit |
EP1112041A1 (en) * | 1998-09-10 | 2001-07-04 | Percardia, Inc. | Tmr shunt |
US6409697B2 (en) | 1999-05-04 | 2002-06-25 | Heartstent Corporation | Transmyocardial implant with forward flow bias |
US6638237B1 (en) * | 1999-08-04 | 2003-10-28 | Percardia, Inc. | Left ventricular conduits and methods for delivery |
US6253768B1 (en) | 1999-08-04 | 2001-07-03 | Percardia, Inc. | Vascular graft bypass |
US6854467B2 (en) * | 2000-05-04 | 2005-02-15 | Percardia, Inc. | Methods and devices for delivering a ventricular stent |
DE10028959C1 (en) * | 2000-06-16 | 2001-11-22 | Winter & Ibe Olympus | Endoscopic instrument has HF electrodes for coagulation or tissue separation positioned in sidewards and distal positions respectively with insulator body between them |
US20020032478A1 (en) * | 2000-08-07 | 2002-03-14 | Percardia, Inc. | Myocardial stents and related methods of providing direct blood flow from a heart chamber to a coronary vessel |
US6533779B2 (en) | 2001-01-16 | 2003-03-18 | Scimed Life Systems, Inc. | PMR catheter and associated methods |
US6976990B2 (en) * | 2001-01-25 | 2005-12-20 | Percardia, Inc. | Intravascular ventriculocoronary bypass via a septal passageway |
US6544220B2 (en) | 2001-02-14 | 2003-04-08 | Scimed Life Systems, Inc. | Fluid jet PMR |
US20030036698A1 (en) * | 2001-08-16 | 2003-02-20 | Robert Kohler | Interventional diagnostic catheter and a method for using a catheter to access artificial cardiac shunts |
US6949118B2 (en) * | 2002-01-16 | 2005-09-27 | Percardia, Inc. | Encased implant and methods |
WO2003068055A2 (en) | 2002-02-11 | 2003-08-21 | Arthrocare Corporation | Electrosurgical apparatus and methods for laparoscopy |
US7008397B2 (en) * | 2002-02-13 | 2006-03-07 | Percardia, Inc. | Cardiac implant and methods |
DE20321839U1 (en) * | 2002-04-12 | 2010-12-30 | Olympus Corporation | Incision device for use with an endoscope |
US20030220661A1 (en) * | 2002-05-21 | 2003-11-27 | Heartstent Corporation | Transmyocardial implant delivery system |
US7326219B2 (en) * | 2002-09-09 | 2008-02-05 | Wilk Patent Development | Device for placing transmyocardial implant |
FR2846520B1 (en) * | 2002-11-06 | 2006-09-29 | Roquette Freres | USE OF MALTODEXTRINS BRANCHED AS BLEACHES OF GRANULATION |
US6928669B2 (en) * | 2003-01-10 | 2005-08-16 | Tyler Pipe Company | Closet carrier system and method of assembly |
US9510900B2 (en) * | 2003-01-21 | 2016-12-06 | Baylis Medical Company Inc. | Electrosurgical device for creating a channel through a region of tissue and methods of use thereof |
EP1651127B1 (en) | 2003-07-16 | 2012-10-31 | Arthrocare Corporation | Rotary electrosurgical apparatus |
JP4425227B2 (en) * | 2006-02-28 | 2010-03-03 | Hoya株式会社 | Endoscopic high-frequency treatment instrument |
DE102006039696A1 (en) * | 2006-08-21 | 2008-02-28 | Hamou, Jacques, Dr. | Apparatus for resection and / or ablation of organic tissue by means of high frequency current and resectoscope |
US11666377B2 (en) | 2006-09-29 | 2023-06-06 | Boston Scientific Medical Device Limited | Electrosurgical device |
US20210121227A1 (en) | 2006-09-29 | 2021-04-29 | Baylis Medical Company Inc. | Connector system for electrosurgical device |
US8747400B2 (en) | 2008-08-13 | 2014-06-10 | Arthrocare Corporation | Systems and methods for screen electrode securement |
US8355799B2 (en) | 2008-12-12 | 2013-01-15 | Arthrocare Corporation | Systems and methods for limiting joint temperature |
US8323279B2 (en) | 2009-09-25 | 2012-12-04 | Arthocare Corporation | System, method and apparatus for electrosurgical instrument with movable fluid delivery sheath |
US8317786B2 (en) | 2009-09-25 | 2012-11-27 | AthroCare Corporation | System, method and apparatus for electrosurgical instrument with movable suction sheath |
US8696659B2 (en) | 2010-04-30 | 2014-04-15 | Arthrocare Corporation | Electrosurgical system and method having enhanced temperature measurement |
US20110295249A1 (en) * | 2010-05-28 | 2011-12-01 | Salient Surgical Technologies, Inc. | Fluid-Assisted Electrosurgical Devices, and Methods of Manufacture Thereof |
US9138289B2 (en) | 2010-06-28 | 2015-09-22 | Medtronic Advanced Energy Llc | Electrode sheath for electrosurgical device |
US8906012B2 (en) * | 2010-06-30 | 2014-12-09 | Medtronic Advanced Energy Llc | Electrosurgical devices with wire electrode |
US8920417B2 (en) * | 2010-06-30 | 2014-12-30 | Medtronic Advanced Energy Llc | Electrosurgical devices and methods of use thereof |
EP2640280B1 (en) | 2010-11-16 | 2022-03-16 | TVA Medical, Inc. | Devices for forming a fistula |
JP6416084B2 (en) | 2012-05-31 | 2018-10-31 | ベイリス メディカル カンパニー インコーポレイテッドBaylis Medical Company Inc. | Medical equipment |
US9486276B2 (en) | 2012-10-11 | 2016-11-08 | Tva Medical, Inc. | Devices and methods for fistula formation |
US11937873B2 (en) | 2013-03-12 | 2024-03-26 | Boston Scientific Medical Device Limited | Electrosurgical device having a lumen |
AU2014236149A1 (en) | 2013-03-14 | 2015-09-17 | Tva Medical, Inc. | Fistula formation devices and methods therefor |
US10631914B2 (en) | 2013-09-30 | 2020-04-28 | Covidien Lp | Bipolar electrosurgical instrument with movable electrode and related systems and methods |
US9526556B2 (en) | 2014-02-28 | 2016-12-27 | Arthrocare Corporation | Systems and methods systems related to electrosurgical wands with screen electrodes |
WO2015138998A1 (en) | 2014-03-14 | 2015-09-17 | Tva Medical, Inc. | Fistula formation devices and methods therefor |
US9649148B2 (en) | 2014-07-24 | 2017-05-16 | Arthrocare Corporation | Electrosurgical system and method having enhanced arc prevention |
US9597142B2 (en) | 2014-07-24 | 2017-03-21 | Arthrocare Corporation | Method and system related to electrosurgical procedures |
US9974599B2 (en) | 2014-08-15 | 2018-05-22 | Medtronic Ps Medical, Inc. | Multipurpose electrosurgical device |
US10646666B2 (en) | 2014-08-27 | 2020-05-12 | Tva Medical, Inc. | Cryolipolysis devices and methods therefor |
US9956029B2 (en) | 2014-10-31 | 2018-05-01 | Medtronic Advanced Energy Llc | Telescoping device with saline irrigation line |
US10603040B1 (en) | 2015-02-09 | 2020-03-31 | Tva Medical, Inc. | Methods for treating hypertension and reducing blood pressure with formation of fistula |
WO2017042743A1 (en) | 2015-09-09 | 2017-03-16 | Baylis Medical Company Inc. | Epicardial access system & methods |
EP3402561B1 (en) | 2016-01-15 | 2024-02-28 | TVA Medical, Inc. | Devices for advancing a wire |
US10874422B2 (en) | 2016-01-15 | 2020-12-29 | Tva Medical, Inc. | Systems and methods for increasing blood flow |
WO2017124062A1 (en) | 2016-01-15 | 2017-07-20 | Tva Medical, Inc. | Devices and methods for forming a fistula |
JP7194676B2 (en) | 2016-09-25 | 2022-12-22 | ティーブイエー メディカル, インコーポレイテッド | Vascular stent device and method |
CA3082622C (en) | 2017-12-05 | 2021-02-02 | Wesley Robert PEDERSEN | Transseptal guide wire puncture system |
JP7284649B2 (en) * | 2019-06-21 | 2023-05-31 | 株式会社メディカロイド | electrosurgical instruments and covers |
US11759190B2 (en) | 2019-10-18 | 2023-09-19 | Boston Scientific Medical Device Limited | Lock for medical devices, and related systems and methods |
US11801087B2 (en) | 2019-11-13 | 2023-10-31 | Boston Scientific Medical Device Limited | Apparatus and methods for puncturing tissue |
US11724070B2 (en) | 2019-12-19 | 2023-08-15 | Boston Scientific Medical Device Limited | Methods for determining a position of a first medical device with respect to a second medical device, and related systems and medical devices |
US11931098B2 (en) | 2020-02-19 | 2024-03-19 | Boston Scientific Medical Device Limited | System and method for carrying out a medical procedure |
US11819243B2 (en) | 2020-03-19 | 2023-11-21 | Boston Scientific Medical Device Limited | Medical sheath and related systems and methods |
US11826075B2 (en) | 2020-04-07 | 2023-11-28 | Boston Scientific Medical Device Limited | Elongated medical assembly |
GB2596067A (en) * | 2020-06-15 | 2021-12-22 | Gyrus Medical Ltd | Electrosurgical instrument with improved sealing |
JP2023521165A (en) | 2020-06-17 | 2023-05-23 | ボストン サイエンティフィック メディカル デバイス リミテッド | electroanatomical mapping system |
US11938285B2 (en) | 2020-06-17 | 2024-03-26 | Boston Scientific Medical Device Limited | Stop-movement device for elongated medical assembly |
US11937796B2 (en) | 2020-06-18 | 2024-03-26 | Boston Scientific Medical Device Limited | Tissue-spreader assembly |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5885272A (en) | 1990-10-30 | 1999-03-23 | Aita; Michael | System and method for percutaneous myocardial revascularization |
US5807388A (en) | 1994-05-25 | 1998-09-15 | The Trustees Of Columbia University In The City Of New York | Myocardial revascularization through the endocardial surface using a laser |
US5683366A (en) | 1992-01-07 | 1997-11-04 | Arthrocare Corporation | System and method for electrosurgical tissue canalization |
US5697882A (en) | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
GB9204218D0 (en) * | 1992-02-27 | 1992-04-08 | Goble Nigel M | A surgical cutting tool |
US5593406A (en) * | 1992-05-01 | 1997-01-14 | Hemostatic Surgery Corporation | Endoscopic instrument with auto-regulating heater and method of using same |
US5840059A (en) | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5769843A (en) | 1996-02-20 | 1998-06-23 | Cormedica | Percutaneous endomyocardial revascularization |
US5810836A (en) | 1996-03-04 | 1998-09-22 | Myocardial Stents, Inc. | Device and method for trans myocardial revascularization (TMR) |
US5832929A (en) | 1996-03-22 | 1998-11-10 | Plc Medical Systems, Inc. | Video assisted thoracoscopic transmyocardial revascularization surgical method |
US5891133A (en) | 1996-03-29 | 1999-04-06 | Eclipse Surgical Technologies, Inc. | Apparatus for laser-assisted intra-coronary transmyocardial revascularization and other applications |
US5766164A (en) | 1996-07-03 | 1998-06-16 | Eclipse Surgical Technologies, Inc. | Contiguous, branched transmyocardial revascularization (TMR) channel, method and device |
US5782823A (en) | 1996-04-05 | 1998-07-21 | Eclipse Surgical Technologies, Inc. | Laser device for transmyocardial revascularization procedures including means for enabling a formation of a pilot hole in the epicardium |
US5840075A (en) | 1996-08-23 | 1998-11-24 | Eclipse Surgical Technologies, Inc. | Dual laser device for transmyocardial revascularization procedures |
US5871495A (en) | 1996-09-13 | 1999-02-16 | Eclipse Surgical Technologies, Inc. | Method and apparatus for mechanical transmyocardial revascularization of the heart |
US5855577A (en) | 1996-09-17 | 1999-01-05 | Eclipse Surgical Technologies, Inc. | Bow shaped catheter |
US5800450A (en) | 1996-10-03 | 1998-09-01 | Interventional Technologies Inc. | Neovascularization catheter |
US5785702A (en) | 1996-10-15 | 1998-07-28 | Eclipse Surgical Technologies, Inc. | Method for non-synchronous laser-assisted transmyocardial revascularization |
US5893848A (en) | 1996-10-24 | 1999-04-13 | Plc Medical Systems, Inc. | Gauging system for monitoring channel depth in percutaneous endocardial revascularization |
US5873366A (en) | 1996-11-07 | 1999-02-23 | Chim; Nicholas | Method for transmyocardial revascularization |
CA2270921A1 (en) | 1996-11-08 | 1998-05-14 | Thomas J. Fogarty | Transvascular tmr device and method |
US5944716A (en) | 1996-12-09 | 1999-08-31 | Scimed Life Systems, Inc. | Radio frequency transmyocardial revascularization corer |
US5807384A (en) | 1996-12-20 | 1998-09-15 | Eclipse Surgical Technologies, Inc. | Transmyocardial revascularization (TMR) enhanced treatment for coronary artery disease |
AU5905098A (en) | 1996-12-23 | 1998-07-17 | Advanced Coronary Intervention | Radio frequency transmyocardial revascularization |
DE69732696T2 (en) | 1997-01-08 | 2006-04-13 | Biosense Webster, Inc., Diamond Bar | MONITORING MYOCARDIAL REVASCULARIZATION |
WO1998031281A1 (en) | 1997-01-21 | 1998-07-23 | Circulase | Transmyocardial revascularization laser system |
US5913853A (en) | 1997-01-30 | 1999-06-22 | Cardiodyne, Inc. | Laser energy device and procedure for forming a channel within tissue |
US5968059A (en) | 1997-03-06 | 1999-10-19 | Scimed Life Systems, Inc. | Transmyocardial revascularization catheter and method |
US5938632A (en) | 1997-03-06 | 1999-08-17 | Scimed Life Systems, Inc. | Radiofrequency transmyocardial revascularization apparatus and method |
US6086534A (en) | 1997-03-07 | 2000-07-11 | Cardiogenesis Corporation | Apparatus and method of myocardial revascularization using ultrasonic pulse-echo distance ranging |
US5906615A (en) * | 1997-03-31 | 1999-05-25 | Femrx, Inc. | Serpentine ablation/coagulation electrode |
US5876373A (en) | 1997-04-04 | 1999-03-02 | Eclipse Surgical Technologies, Inc. | Steerable catheter |
US5827203A (en) | 1997-04-21 | 1998-10-27 | Nita; Henry | Ultrasound system and method for myocardial revascularization |
IL120811A0 (en) | 1997-05-08 | 1997-09-30 | Laser Ind Ltd | Method and apparatus for performing transmyocardial revascularization |
BR9804941A (en) | 1997-05-08 | 1999-08-24 | Bard Inc C R | Tmr stentor and distribution system |
JP2001512039A (en) | 1997-07-22 | 2001-08-21 | ユナイテッド ステイツ サージカル コーポレイション | Laser ablation device and control system |
JP2001510701A (en) | 1997-07-22 | 2001-08-07 | ジェイムズ コーリア, | Apparatus and method for transmyocardial vascular regeneration by laser ablation |
AU8901598A (en) | 1997-08-07 | 1999-03-01 | Cardiogenesis Corporation | System and method of intra-operative myocardial revascularization using pulsed sonic energy |
AU9102798A (en) | 1997-08-14 | 1999-03-08 | Mark G Fontenot | Multi-channel transmyocardial laser revascularization |
US5885276A (en) | 1997-12-02 | 1999-03-23 | Galil Medical Ltd. | Method and device for transmyocardial cryo revascularization |
US6093185A (en) * | 1998-03-05 | 2000-07-25 | Scimed Life Systems, Inc. | Expandable PMR device and method |
-
1999
- 1999-02-24 US US09/256,831 patent/US6217575B1/en not_active Expired - Lifetime
-
2000
- 2000-02-24 CA CA002362921A patent/CA2362921A1/en not_active Abandoned
- 2000-02-24 JP JP2000600571A patent/JP2002537059A/en active Pending
- 2000-02-24 WO PCT/US2000/004977 patent/WO2000049956A1/en not_active Application Discontinuation
- 2000-02-24 EP EP00913630A patent/EP1154726A1/en not_active Withdrawn
-
2001
- 2001-03-21 US US09/814,314 patent/US20010049523A1/en not_active Abandoned
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704222B2 (en) | 1998-09-10 | 2010-04-27 | Jenavalve Technology, Inc. | Methods and conduits for flowing blood from a heart chamber to a blood vessel |
US7736327B2 (en) | 1998-09-10 | 2010-06-15 | Jenavalve Technology, Inc. | Methods and conduits for flowing blood from a heart chamber to a blood vessel |
US8216174B2 (en) | 1998-09-10 | 2012-07-10 | Jenavalve Technology, Inc. | Methods and conduits for flowing blood from a heart chamber to a blood vessel |
US8597226B2 (en) | 1998-09-10 | 2013-12-03 | Jenavalve Technology, Inc. | Methods and conduits for flowing blood from a heart chamber to a blood vessel |
US8285393B2 (en) | 1999-04-16 | 2012-10-09 | Laufer Michael D | Device for shaping infarcted heart tissue and method of using the device |
US20030137008A1 (en) * | 2000-03-28 | 2003-07-24 | Hidetoshi Nozaki | Solid state imaging device having a photodiode and a MOSFET and method of manufacturing the same |
US20040267337A1 (en) * | 2003-06-30 | 2004-12-30 | Cardiac Pacemakers, Inc. | Method and apparatus for diverting blood flow during ablation procedures |
US7540853B2 (en) * | 2003-06-30 | 2009-06-02 | Cardiac Pacemakers, Inc. | Method and apparatus for diverting blood flow during ablation procedures |
US11517431B2 (en) | 2005-01-20 | 2022-12-06 | Jenavalve Technology, Inc. | Catheter system for implantation of prosthetic heart valves |
WO2008063506A2 (en) * | 2006-11-13 | 2008-05-29 | Co-Repair, Inc. | Method for the treatment of heart tissue |
WO2008063506A3 (en) * | 2006-11-13 | 2009-01-08 | Co Repair Inc | Method for the treatment of heart tissue |
US11357624B2 (en) | 2007-04-13 | 2022-06-14 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
US8998892B2 (en) | 2007-12-21 | 2015-04-07 | Atricure, Inc. | Ablation device with cooled electrodes and methods of use |
US8915878B2 (en) | 2007-12-21 | 2014-12-23 | Atricure, Inc. | Ablation device with internally cooled electrodes |
US8353907B2 (en) | 2007-12-21 | 2013-01-15 | Atricure, Inc. | Ablation device with internally cooled electrodes |
US10993805B2 (en) | 2008-02-26 | 2021-05-04 | Jenavalve Technology, Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US11154398B2 (en) | 2008-02-26 | 2021-10-26 | JenaValve Technology. Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US11564794B2 (en) | 2008-02-26 | 2023-01-31 | Jenavalve Technology, Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US11589981B2 (en) | 2010-05-25 | 2023-02-28 | Jenavalve Technology, Inc. | Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent |
US11185405B2 (en) | 2013-08-30 | 2021-11-30 | Jenavalve Technology, Inc. | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
US11337800B2 (en) | 2015-05-01 | 2022-05-24 | Jenavalve Technology, Inc. | Device and method with reduced pacemaker rate in heart valve replacement |
US11065138B2 (en) | 2016-05-13 | 2021-07-20 | Jenavalve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system |
US11197754B2 (en) | 2017-01-27 | 2021-12-14 | Jenavalve Technology, Inc. | Heart valve mimicry |
US11199940B1 (en) * | 2020-04-21 | 2021-12-14 | Corel Corporation | Three-dimensional operations based on planar projections in graphic user interfaces |
Also Published As
Publication number | Publication date |
---|---|
WO2000049956A1 (en) | 2000-08-31 |
EP1154726A1 (en) | 2001-11-21 |
US6217575B1 (en) | 2001-04-17 |
CA2362921A1 (en) | 2000-08-31 |
JP2002537059A (en) | 2002-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6217575B1 (en) | PMR catheter | |
US6416490B1 (en) | PMR device and method | |
EP1307257B1 (en) | Tortuouse path injection device and method | |
US6893421B1 (en) | Catheter shaft assembly | |
US6343605B1 (en) | Percutaneous transluminal myocardial implantation device and method | |
US6613017B1 (en) | Controlled depth injection device and method | |
US7947040B2 (en) | Method of surgical perforation via the delivery of energy | |
US7195637B2 (en) | Method and device for inserting leads into coronary veins | |
US20060111704A1 (en) | Devices, systems, and methods for energy assisted arterio-venous fistula creation | |
US9597146B2 (en) | Method of surgical perforation via the delivery of energy | |
JP2002535033A (en) | Equipment for treatment of atrial arrhythmias | |
US20210307823A1 (en) | Method of surgical perforation via the delivery of energy | |
EP3912585A1 (en) | Radiofreqeuncy ablation catheter for septal reduction therapy having cooling effect | |
US20220061915A1 (en) | Rf ablation catheter for septal reduction therapy having cooling effect | |
US20230355292A1 (en) | Radial compatible catheter for peri-vascular fluid injection | |
US20090118673A1 (en) | Needle injection catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |